Patent Grant
10960399
The present disclosure provides systems for performing thermal cycling (also “thermocycling” herein) of a fluid (also “sample” or “sample fluid” herein). The systems herein can be used for thermocycling a sample fluid to perform biological or biochemical analysis. In some examples, the systems herein can be used for thermocycling a sample fluid comprising a deoxyribonucleic acid (DNA) target to perform polymerase chain reaction (PCR). The systems can be cartridge-based systems (also “cartridges,” “cartridge-based thermocyclers” or “cassettes” herein) that enable low-cost, disposable PCR systems to be realized. In some cases, the cartridges can be real-time, multiplexed systems (also “multiplexed assays” herein). The cartridges can be coupled to other PCR system components, such as, for example, one or more other cartridges and/or an instrument. In some implementations, PCR systems comprising disposable cartridge system(s) coupled with a durable instrument can be provided.
Systems of the present disclosure include cartridges that are configured to move fluid between distinct chambers. Each chamber can have a given temperature, composition, volume and/or shape. Individual chambers can be heated, cooled, and/or compressed to mix fluid within the chamber or to propel fluid in the chamber into another chamber. Further, the chambers can be shaped to inhibit trapping of air bubbles. The chambers can be configured to allow rapid thermal equilibration. In some implementations, the cartridge comprising the chambers can have a laminate construction.
The present disclosure relates to a thermocycler comprising a first chamber for holding a fluid at a first average temperature and a second chamber for holding the fluid at a second average temperature. The second chamber is in fluid communication with the first chamber, wherein the fluid is transferred between the first chamber and the second chamber to achieve a transition from the first average temperature to substantially the second average temperature or vice versa at a rate of 10 μL° C./second or more. The first and second chambers can be provided on a disposable portion of the thermocycler. In some cases, the transition from the first average temperature to substantially the second average temperature or vice versa can be achieved at a rate of 25 μL° C./second or more. The thermocycler can have a cycle time of 10 seconds or less. The fluid can have a starting volume of about 25 μL or more. In one embodiment, the first average temperature is nominally between about 55° C. (328 K) and about 65° C. (338 K), and the second average temperature is nominally about 95° C. (368 K). In one embodiment, the fluid has a starting volume of about 25 μL or more, for example, about μL. In one embodiment, the fluid is transferred between the first chamber and the second chamber to achieve the transition from the first average temperature to substantially the second average temperature or vice versa within 5 seconds or less, 4 seconds or less, 3 seconds or less, 2 seconds or less, or 1 second or less. In one embodiment, the thermocycler comprises a filling and/or venting channel, wherein the venting channel prevents gases from being trapped during filling.
The present disclosure is directed to a method for performing polymerase chain reaction (PCR) comprising providing a first fluid holding chamber having a first average temperature, providing a second fluid holding chamber having a second average temperature, mechanically actuating fluid transfer between the first chamber and the second chamber, and completing the PCR within a total thermocycling time that is at least about 9 times shorter than a corresponding thermocycling time on a conventional system. The method can further comprise completing the PCR amplification within a total thermocycling time of less than about 4 minutes. The method can further comprise completing the PCR within a total thermocycling time that is at least about 11.5 times shorter than the corresponding thermocycling time on a conventional system. The method can further comprise completing the PCR at a PCR efficiency that is substantially the same as a PCR efficiency of the conventional system. The PCR efficiency can be at least about 92%. In one embodiment, the method further comprises detecting PCR amplification by monitoring the first chamber, the second chamber or a channel between the first chamber and the second chamber. Monitoring includes optical multiplexing. In one embodiment, a PCR amplification method is completed in a time that is about 11.5 times shorter than the corresponding thermocycling time on a conventional system. In one instance, the PCR efficiency is substantially the same as a PCR efficiency of the conventional system. In another instance, the PCR amplification is equal to an amplification of the conventional system. In one embodiment, the PCR method is complete upon reaching a predetermined number of cycles.
The present disclosure provides a low-cost polymerase chain reaction (PCR) system comprising a cartridge configured for transferring a fluid between a first chamber and a second chamber maintained at distinct temperatures, wherein the cartridge has a laminate construction defining the first chamber and the second chamber, and wherein the transfer of the fluid between the first chamber and the second chamber is for thermocycling the fluid. The laminate construction can define the first chamber and the second chamber in the absence of mechanical force or mechanical actuation. In one embodiment, the cartridge is disposable. In one embodiment, the volumes of the first chamber and the second chamber depend on the thickness of individual layers of the laminate construction. In one implementation, the laminate construction comprises a first outer plastic layer, a first pressure sensitive adhesive layer, a second pressure sensitive adhesive layer, a second outer plastic layer, and optionally a cover. In one embodiment, the cover is a rigid structure. In one embodiment, the cover is bonded to the first outer plastic layer or the second outer plastic layer. In another embodiment, the first outer plastic layer or the second outer plastic layer is a membrane layer. In one embodiment, the starting volume of the fluid is at least about 25 μL, at least about 50 μL, and/or at least about 60 μL. In one embodiment, the height of the first chamber and the second chamber is 250 μm or less. In one embodiment, the first chamber or the second chamber has a tear drop shape. In another embodiment, the first chamber or the second chamber or both are shaped to achieve a reduced number of nucleation sites.
In one embodiment, the low-cost polymerase chain reaction (PCR) system has a laminate construction comprising an optical window. In one embodiment, the optical window provides an optical path to a portion of a fluid path between the first chamber and the second chamber. In one embodiment, a sample volume is interrogated through the optical window. In another embodiment, the optical window comprises a light directing feature. A light directing feature includes, without limitation, a lens, prism, Fresnel lens or any combination thereof. In a further embodiment, the system further comprises a blocking feature to obstruct stray light from an excitation source. Blocking features include, without limitation, foil, coatings or a combination thereof.
The present disclosure further provides a multiplexed assay comprising a plurality of thermocycling units. Each thermocycling unit comprises a first chamber for holding a fluid at a first average temperature. Each thermocycling unit further comprises a second chamber for holding the fluid at a second average temperature. The second chamber is in fluid communication with the first chamber. The first chamber and the second chamber each have a non-zero volume prior to holding the fluid. In one embodiment, the assay further comprises a detector coupled to at least a subset of the plurality of thermocycling units. In one embodiment, the detector is dedicated to a single thermocycling unit of the plurality of thermocycling units. In one embodiment, the detector is shared by at least a subset of the plurality of thermocycling units. In one embodiment, at least a subset of the plurality of thermocycling units are identical. In another embodiment, a first subsct of the plurality of thermocycling units has a different configuration than a second subset of the plurality of thermocycling units.
Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings or figures (also “FIG.” and “FIGs.” herein), of which:
While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions occurs to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein are employable. Tt shall be understood that different aspects of the invention can be appreciated individually, collectively, or in combination with each other.
The term “polymerase chain reaction (PCR),” as used herein, generally refers to any variation on the basic process or operation of amplifying a single or a few copies of a specific region of a DNA strand (also referred to as “DNA target,” “target,” or “target DNA” herein) to generate copies of a particular DNA sequence. In some examples, DNA fragments of between about 100 and 40,000 base pairs (bp) can be amplified. Primers (e.g., short DNA fragments) containing sequences complementary to the target region along with a DNA polymerase (e.g., Taq polymerase or another heat-stable DNA polymerase) can be provided to enable selective and repeated amplification. As PCR progresses, the DNA generated can itself be used as a template for replication. Components needed to perform PCR can include, but are not limited to, primers, DNA polymerase, DNA building blocks (e.g., deoxynucleoside triphosphate nucleotides), buffer solution, divalent cations (e.g., magnesium or manganese ions), and monovalent cations (e.g., potassium ions). Thermal cycling (e.g., alternate heating and cooling of the PCR sample) through a defined series of temperature steps can be used. In some examples, a series of 20-40 repeated temperature changes (also “cycles” herein) can be used, with each cycle comprising two or three discrete temperature steps, as described in greater detail below. In some cases, the cycling can be preceded by and/or followed by additional temperature step(s). The temperatures used and the length of time they are applied in each cycle can depend on a variety of parameters (e.g., enzyme used for DNA synthesis, concentration of divalent ions and nucleotides in the reaction, melting temperature of the primers).
The term “amplification,” as used herein, generally refers to a relationship between an amplified target concentration and an initial target concentration. The amplification can be defined as, for example, A=Cx/C0, where Cx is the amplified target concentration (e.g., DNA copies per volume) and C0 is the initial target concentration (e.g., DNA copies per volume). In an example, an initial concentration of Bacillus Atrophaeus (B. Atro) DNA of about C0=105 copies per milliliter (mL) is run through 30 cycles of PCR thermocycling to achieve an amplified target concentration of about Cx=109 copies/mL, and thus an amplification of about A=108. At a PCR efficiency of 100%, each cycle can double the target population, and at 30 cycles, an amplification of about 230 or about A=109 can be achieved. Since the amplification in this example is less than 109, the PCR efficiency is less than 100%. For example, the PCR efficiency can be about 84% or about 92%. In some examples, PCR can continue to a given amplification, where a target population (also “target concentration” herein) is easily observed (e.g., by observing an optical signal produced by a bound fluorescent probe). In some examples, reaching a given number of cycles can be used to define completion of the PCR (i.e., PCR completion can be defined as a point when a given number of cycles have been completed). Amplification includes, without limitation, nucleic acid amplification. Exemplary nucleic acid amplification reactions include, without limitation, polymerase chain reaction (PCR), strand displacement amplification (SDA), helicase dependent amplification (HDA), loop-mediated isothermal amplification (LAMP), transcription-mediated amplification (TMA), nucleic acid sequence based amplification (NASBA) and self-sustained sequence replication (3SR). Nucleic acid amplification reactions include both real-time and end-point reactions.
The term “cycle time,” as used herein, generally refers to the time required to accomplish a denaturing step, an annealing step, and an extension step in a nucleic acid amplification reaction. In an exemplary embodiment, these steps are done at three distinct temperatures or two distinct temperatures. In an example where these steps are accomplished at two distinct temperatures in two respective cartridge chambers, the cycle time is the residence time of a sample in two consecutive chambers (e.g., a hot chamber and a cold chamber) of a cartridge.
The term “ramp time,” as used herein, generally refers to the time required for the bulk of a fluid to ramp from a first temperature to a second temperature.
The term “extension time,” as used herein, generally refers to the time required for a DNA polymerase (e.g., Taq polymerase) to extend the length of the copied molecule. A typical extension rate for Taq polymerase can be 1000 nucleotides per second at 72° C. The extension time for a PCR product on the order of 200-400 bp using the cartridge-based thermocyclers of the present disclosure can be, for example, 1-2 seconds.
The term “melt time,” as used herein, generally refers to the time required to achieve adequate melting of the DNA of the copied molecule (e.g., by disrupting hydrogen bonds between complementary bases, yielding single-stranded DNA molecules).
The term “dwell time,” as used herein, generally refers to the time that a sample resides at each temperature. For example, for two-temperature PCR, cycle time can equal the dwell time times two. In some cases, cycle time can be a sum of a first dwell time at a first temperature and a second dwell time at a second temperature. In an example, the dwell time equals the residence time of a sample in an individual chamber (e.g., a hot chamber or a cold chamber) of a cartridge. In some cases, dwell time can equal ramp time plus extension time (e.g., in a cold chamber). In some cases, dwell time can equal ramp time plus melt time (e.g., in a hot chamber). In some cases, the melt time can be less than the extension time. Thus, dwell times based on ramp time plus extension time can provide an upper limit for dwell times in both hot side and cold side chambers. In an example, the dwell time using the cartridge-based thermocyclers of the present disclosure can be 5 seconds and can include 3 seconds of ramp time and 2 seconds of extension time.
In various implementations, a reference to time (including, but not limited to, cycle time, ramp time, extension time, melt time, dwell time) in a nucleic acid amplification cycle is dependent, at least in part, on the number of nucleic acids to be amplified, the sequence of nucleic acids to be amplified, the oligonucleotide primers used in the amplification reaction, and any combination thereof. In one embodiment, the thermocyclers and methods provided herein are useful for amplifying a nucleic acid comprising between about 50 base pairs (bp) and about 50,000 bp, between about 50 bp and about 40,000 bp, between about 50 bp and about 30,000 bp, between about 50 bp and about 20,000 bp, between about 50 bp and about 10,000 bp, or between about 50 bp and about 5,000 bp. In one embodiment, the thermocyclers and methods provided herein are useful for amplifying a nucleic acid comprising between about 50 bp and about 5,000 bp, between about 50 bp and about 4,000 bp, between about 50 bp and about 3,000 bp, between about 50 bp and about 2,000 bp, between about 50 bp and about 1,000 bp, or between about 50 bp and about 500 bp. In another embodiment, the thermocyclers and methods provided herein are useful for amplifying a nucleic acid comprising between about 50 base pairs bp and about 500 bp, between about 50 bp and about 400 bp, between about 50 bp and about 300 bp, between about 50 bp and about 200 bp, between about 100 bp and about 1,000 bp, between about 100 bp and about 500 bp, between about 100 bp and about 400 bp, between about 100 bp and about 300 bp, between about 150 bp and about 1,000 bp, between about 150 bp and about 500 bp, between about 150 bp and about 400 bp, or between about 150 bp and about 300 bp. In one embodiment, the nucleic acid amplification for a nucleic acid template comprising from about 50 bp to about 5,000 bp is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more efficient. In one embodiment, a nucleic acid amplification cycle time for a nucleic acid template comprising from about 50 bp to about 5,000 bp is less than about 60 seconds, less than about 50 seconds, less than about 40 seconds, less than about 30 seconds, less than about 20 seconds, less than about 10 seconds, or less than about 5 seconds.
Cartridge-Based Rapid Thermocyclers
The disclosure provides systems for performing thermal cycling (also “thermocycling” herein) of a fluid (also “sample” or “sample fluid” herein). The systems herein can be used for thermocycling a sample fluid to perform biological or biochemical analysis. In some examples, the systems herein can be used for thermocycling a sample fluid comprising a deoxyribonucleic acid (DNA) target to perform polymerase chain reaction (PCR). The systems can be cartridge-based systems (also “cartridges” or “cartridge-based thermocyclers” herein) that enable low-cost, disposable PCR systems to be realized. In some cases, the cartridges can be real-time, multiplexed systems (also “multiplexed assays” herein). The cartridges can be coupled to other PCR system components, such as, for example, one or more other cartridges and/or an instrument. In some implementations, PCR systems comprising disposable cartridge system(s) coupled with a durable instrument can be provided.
The cartridges can be configured to move fluid between distinct chambers. Each chamber can have a given temperature, composition, volume and/or shape. Individual chambers can be heated, cooled, and/or compressed to mix fluid within the chamber or to propel fluid in the chamber into another chamber. Further, the chambers can be shaped to inhibit trapping of air bubbles. The chambers can be configured to allow rapid thermal equilibration. The chambers have any shape that does not interfere with the movement of fluid between chambers, which includes generally planar or bubble-like shapes, including hemispherical and spherical shapes.
Reference will now be made to the figures, wherein like numerals refer to like parts throughout. It will be appreciated that the figures (and features therein) are not necessarily drawn to scale.
The thermocycler can comprise one or more parts. In some examples, the thermocycler can comprise a disposable portion 1 and a durable or reusable portion 2. The disposable portion (also “disposable” herein) can be provided, for example, on a single cartridge or cartridge portion, or on (e.g., spread across) multiple cartridges or cartridge portions. In one embodiment, the durable portion of a thermocycler comprises a receptacle or attachment means for receiving the disposable portion. In one example, the components of the disposable portion shown 1 are provided on a single cartridge. In one embodiment, this cartridge couples to another cartridge. In a further embodiment, this cartridge couples with an instrument or analyzer. In some cases, the disposable is used once and disposed of. For example, all parts of the disposable are discarded. The durable or reusable portion can be provided, for example, on a durable instrument or analyzer. In some cases, the durable instrument and at least a subset or all parts associated with can be reused through the life of the instrument. In one embodiment, for simultaneous thermocycling of a plurality of samples, a plurality of cartridges are used simultaneously with one reusable portion or instrument. For example, the multiple cartridges are aligned in parallel.
In an example, the disposable comprises of a polydimethylsiloxane (PDMS) top block 3 which has cavities molded within it. Two shallow chambers, left chamber 4 (e.g., at the first temperature T1) and right chamber 5 (e.g., at the second temperature T2), can be provided. Each chamber can have nominal dimensions of about 12 mm in diameter and about 0.5 mm in height. The chambers can be connected by a connecting channel 6 with a length of about 5 mm and a cross-section with a height of about 0.30 mm and a width of about 0.50 mm. The areas above the chambers can be compliant and can be deformed such that the internal volume of the chamber can be changed to as little as, for example, 10% of its original undeformed volume of π×(12 mm)2/4×(0.5 mm) or about 56 microliters (μL).
In some examples, cartridges of the disclosure can comprise chambers that are configured to be deformed on one side (e.g., along a top surface of each chamber) or on two sides (e.g., along a top and a bottom surface of each chamber). In some cases, individual chambers can be deformed using different configurations. In some examples, the deformation can result in a change of internal volume of the chamber to less than about 90% of its original undeformed volume, less than about 80% of its original undeformed volume, less than about 70% of its original undeformed volume, less than about 60% of its original undeformed volume, less than about 50% of its original undeformed volume, less than about 40% of its original undeformed volume, less than about 30% of its original undeformed volume, less than about 20% of its original undeformed volume, less than about 10% of its original undeformed volume, and the like.
In various implementations, the boundaries of the chambers and/or the channels connecting said chambers are defined by any sealing means or barrier which closes a chamber to prevent movement of fluid into or out of the chamber. In one embodiment, any chamber or component of a thermocycler comprises one or more openings with sealing means to allow for the addition or removal of gases, solids and/or fluids, e.g., an inlet or port. In one example, an opening comprises a seal or valve. In one embodiment, a chamber and/or channel is opened by an external force applied to or next to the chamber and/or channel. In one example, the seal is a burstable seal. Methods to open a seal include, without limitation, application of pressure, mechanical actuation, heat and chemical reaction. Barriers include those which are fixed, movable or alterable components inserted into channels of the cartridge. Barriers and seals are alternatively a component of a durable portion of a thermocycling unit. In one embodiment, barriers are an external force provided by the durable portion of a thermocycling unit, for example, a clamp. In one embodiment, some of the channels remain open during a thermocycling reaction, while others may remain closed. In one example, a channel and/or chamber is opened or closed at any time point prior to or during a thermocycling reaction. Once a barrier or seal is opened, a substance, such as a fluid, in many implementations, is moved from one chamber to another, for example, by pressure from an actuator.
In some implementations, channels 7 and 8 can allow filling and extracting of fluid (e.g., sample) from the chambers 4 and 5, respectively, via a filling or collecting device (e.g., a syringe, or ancillary chambers on the same disposable). The channels can have a cross-section with a height of about 0.3 mm and a width of about 0.5 mm. A plate 9 (e.g., a thin plate of glass or some other suitable material) can be bonded to the PDMS top block (e.g., using a plasma cleaning process). The bonding can allow very high adhesion between the two materials to support large internal pressures caused by vapor pressure and compression of the chamber volumes. The plate 9 can have a thickness of, for example, about 0.14 mm.
The durable instrument 2 can interact with the disposable 1. The parts or components of the durable instrument 2 that interact with the disposable 1 can include, for example, actuator heads 10 and 11. The actuator heads can deform the fluidic chambers to move fluid from one chamber (e.g., the chamber held at T1) to the other chamber (e.g., the chamber held at T2), or vice versa, over multiple cycles (e.g., between 20 and 30).
In some implementations, the plate 9 can be supported and in contact with heater blocks 12 and 13. The heater blocks can be formed of a heat conductive material such as, for example, aluminum, copper or other metals. The heater blocks can be kept at temperatures T1 and T2 by heaters 14 and 15, respectively. In some cases, the heaters 14 and 15 can be thin film resistive heaters with leads 16 and 17, respectively, for providing current to each heater. In other cases, the heater blocks can be heated by other heaters 14, 15, such as, for example, thermoelectric heaters, thin film heaters, etc. The two heater blocks can be separated by an air gap to minimize temperature coupling between the two chambers. Temperature probes 18 and 19 (e.g., thermocouples) can be used to monitor the heater block temperatures. In an additional embodiment, a means for measuring temperature, e.g., temperature probe, is coupled to or in contact with one or more regions of the disposable, for example, one or more chambers. The temperature probes can be used in a temperature control feedback loop to keep the temperatures constant at their respective set-points (e.g., T1 and T2). In one embodiment, the control feedback loop is provided on the durable instrument. For example, the thermocouple signals can be acquired by a data acquisition board and further processed on a processing or computing unit of the durable instrument. Based on the temperature reading received and/or other control parameters (e.g., temperature programming, optical detection signal of reaction progress etc.), the durable instrument provide control signals to one or more components (e.g., heater voltage or current controls, actuators, etc.) in a feedback mechanism.
In yet other cases, heater blocks are not be used; instead, heating can be provided directly to the chambers (or to a structure surrounding the chambers, such as, for example, the plate 9 and/or the top block 3, or a laminate layer on a laminated cartridge described elsewhere herein). For example, convective heating (or cooling) using phase change or a fluid such as oil, air or water can be used instead. Any description herein of heating of chambers equally applies to cooling of chambers at least in some configurations.
In one embodiment, one or more heaters are warmed up (or alternatively cooled down) to a desired reaction temperature prior to performing a thermocycling reaction. In another embodiment, one or more heaters are warmed up (or alternatively cooled down) during the course of a thermocycling reaction. In one example, a heater is warmed up to a desired temperature in less than about 10 minutes, less than about 9 minutes, less than about 8 minutes, less than about 7 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, less than about 1 minute, or less than about 30 seconds.
In some embodiments, the durable portion of a thermocycler provided herein comprises a plurality of heaters, wherein each heater provides temperature control for one or more chambers of a cartridge. For example, the thermocycler comprises 1, 2, 3, 4 or more heaters. In another embodiment, the thermocycler comprises one or more cooling elements. In one embodiment, a thermocycler comprises two heaters which provide temperature control for one chamber of a cartridge, for example, the cartridge is disposed between the two heaters. In another example, one or more heaters provide temperature control to one or more cartridges simultaneously, wherein the cartridges are aligned in parallel.
In various embodiments, the cartridges of the disclosure allow very short dwell times for each thermal cycle to be achieved. This can be an important factor in establishing a fast time-to-result PCR test. The timescales of molecular biological reactions associated with PCR can be much shorter than 1 second. Therefore, the time-determining factor in rapid thermocycling can be the length of dwell time for each thermal cycle. In this example, for 20 cycles at about 5 second dwell times in each chamber (cycle time of about 10 seconds), the total thermocycling time can be about 200 seconds (3.3 minutes). Most commercial thermocyclers (e.g., ABI 7900) require 30 minutes to an hour to run this PCR because of the length of time needed to heat and cool the thermal mass of these systems (e.g., disposable tubes and/or plates held in metal blocks). Thus, PCR with a given PCR efficiency (e.g., 92% PCR efficiency) can be completed within a total thermocycling time that is at least 9 times (e.g., 30×60 seconds/200 seconds=9) shorter than the corresponding thermocycling time on a conventional system. In another example, a Roche LightCycler II 480 Real Time PCR System can require about 23 minutes to complete 20 cycles, while a cartridge with two-sided heating and dwell times of about 3 seconds, described in greater detail elsewhere herein, can perform this PCR in about 2 minutes (e.g., 20×3 seconds×2=120 seconds=2 minutes), or about 11.5 faster (e.g., 23 minutes/2 minutes=11.5). In some examples, cartridges of the disclosure can complete a PCR with a given PCR efficiency within a total thermocycling time that is shorter than the corresponding (e.g., having the same PCR efficiency) thermocycling time on a conventional system by a factor of at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 9.5, at least about 10, at least about 10.5, at least about 11, at least about 11.5, at least about 12, at least about 12.5, at least about 13, at least about 14, at least about 15, or more. In some examples, the PCR efficiency can be at least about 84%, 86%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, and the like. In an example, PCR with a PCR efficiency of at least 92% is completed within a total thermocycling time that is at least about 9 times shorter than the thermocycling time on a conventional system with the same PCR efficiency. In another example, PCR with a PCR efficiency of at least 92% is completed within a total thermocycling time that is at least about 11.5 times shorter than the thermocycling time on a conventional system with the same PCR efficiency.
In some examples, the total thermocycling time can be less than about 10 minutes, less than about 8 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, less than about 1 minute, less than about 0.5 minute, and the like. In some examples, a cartridge-based thermocycler has a total thermocycling time of about 5 minutes, about 4 minutes, about 3 minutes, about 2 minutes, about 1 minute, about 0.5 minute, or less. In other examples, the total thermocycling time to achieve a PCR efficiency of at least 85% is less than about 15 minutes, less than about 10 minutes, less than about 9 minutes, less than about 8 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, less than about 1 minute, less than about 0.5 minute, and the like. In other examples, the total thermocycling time to achieve a PCR efficiency of at least 90% is less than about 15 minutes, less than about 10 minutes, less than about 9 minutes, less than about 8 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, less than about 1 minute, less than about 0.5 minute, and the like. In other examples, the total thermocycling time to achieve a PCR efficiency of at least 91% is less than about 15 minutes, less than about 10 minutes, less than about 9 minutes, less than about 8 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, less than about 1 minute, less than about 0.5 minute, and the like. In other examples, the total thermocycling time to achieve a PCR efficiency of at least 92% is less than about 15 minutes, less than about 10 minutes, less than about 9 minutes, less than about 8 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, less than about 1 minute, less than about 0.5 minute, and the like. In other examples, the total thermocycling time to achieve a PCR efficiency of at least 95% is less than about 15 minutes, less than about 10 minutes, less than about 9 minutes, less than about 8 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, less than about 1 minute, less than about 0.5 minute, and the like.
The cartridges of the present disclosure can be used as multiplexed assays. In one aspect, a thermocycling unit provided herein comprises or is operably connected to a detector. For example, one or more components of a cartridge are configured to enable detection of a sample within the component. For example, the detector detects the existence of an analyte in the sample or the amount of a signal indicative of a characteristic of the sample. Signals include, without limitation, luminescence, fluorescence, turbidity, radioactivity and electrical currents. In an exemplary embodiment, a nucleic acid analyte is detected using a detectable label. Exemplary labels include, without limitation, radiolabels, intercalating dyes, enzymes, haptens, chemiluminescent molecules, and fluorescent molecules. In some implementations, one or more regions of the cartridge (e.g., one or more of the chambers, a region in the fluid flow path between chambers, etc.) can be monitored to detect amplification of the target DNA (e.g., using optical or other detection methods, such as bioimpedance and colorimetry). In some cases, the detection can be implemented through optical multiplexing by using one or more fluorescent probes. In one example, each target DNA sequence can be detected by a fluorescent label (also “fluorophore” herein), with a different label corresponding to each target. In another example, multiple labels can be applied to each target DNA sequence. The detection can be performed in real-time. For example, multiplexed real-time PCR can be used to identify the presence and/or the quantity of particular sequences of DNA.
Further, the thermocycling unit can be reproduced multiple times on a more complicated cartridge (e.g., a disposable cartridge) or cassette. For example, multiple thermocycling units can be deployed within a cartridge to perform a multiplexed assay. In some cases, at least a subset or all of the thermocycling units can be identical. In other cases, one or more of the thermocycling units can be unique (e.g., each thermocycling unit can have a different configuration including, but not limited to, chamber shape, volume, temperature etc.). In some implementations, one or more of the thermocycling units can have a dedicated detector. For example, each of the thermocycling units can have a dedicated detector. Alternatively, at least a subset of the thermocycling units can share a detector. For example, each thermocycling unit can have a switching element in front of a time multiplexed detector. Individual detectors can be suitable or configured for detecting PCR on one or more of the thermocycling units.
The cartridges of the present disclosure can comprise additional cartridge portions or be coupled to one or more other cartridges. For example, individual thermocycling units can be linked to one or more reaction chambers (e.g., on the additional cartridge portion or on another cartridge) for implementing sample preparation. In some cases, multiple thermocycling units can be linked to a single set of reaction chambers for implementing sample preparation. In other cases, multiple thermocycling units can be linked to multiple sets of reaction chambers for implementing sample preparation. In an example, a first subset of thermocycling units can be linked or connected to a first set of reaction chambers while a second subset of thermocycling units can be linked or connected to a second set of reaction chambers. In another example, one or more individual thermocycling units can each be linked to its own set of reaction chambers. Each set of reaction chambers can include, for example, 1, 2, 3, 4, 6, 8, 10 or more reaction chambers.
Starting volume (also “sample starting volume” or “sample volume” herein) can be important in PCR (e.g., for high sensitivity PCR reactions). At low target analyte concentration, a larger sample volume can facilitate detection by increasing probability of the analyte being present in the sample for PCR analysis. Because of sample composition variability (e.g., in real human samples such as urine or saliva), the sample can be processed through a pre-filter to remove, for example, solid matter (e.g., insoluble material) prior to a purification step. In one aspect, the cartridges provided herein comprise or are coupled to a chamber or vessel for sample preparation. In one example, the sample is processed prior to addition to a cartridge or processed, in whole or in part, in one or more chambers or components of a cartridge. A first step in purification can be to lyse all the organisms of interest (e.g., bacteria, viruses, etc.) to release total nucleic acid. A next step in purification can involve a solid phase material (e.g., filter or beads) with an affinity for the nucleic acid or molecule of interest. After affinity capture of the nucleic acid to the solid phase material, the nucleic acid can be washed with a wash solution prior to elution with water. The elution can contain the purified nucleic acid to be used for PCR analysis. Using as much of the elution as possible for PCR can be desirable in order to increase or maximize the sensitivity. For example, a PCR starting volume of more than about 25 μL (e.g., 50 μL) can be used to achieve improved sensitivity. This can allow the PCR to proceed with low target concentrations (e.g., 10 copies/μL). Therefore, rapid thermocyclers of the disclosure can be configured to provide an increased heat transfer rate (° C./second) while ensuring that this heat transfer rate can be achieved with a reasonable starting volume. In one embodiment, a sample preparation chamber or vessel comprises, or is connected to an auxiliary chamber which comprises, sample preparation reagents such as Lysozyme or Proteinase K. In one embodiment, a sample preparation chamber or vessel comprises, or is connected to an auxiliary chamber which comprises, a solid support for immobilizing an analyte, e.g., nucleic acid, in the sample. Solid supports include magnetic supports, such as beads, that can be manipulated by a magnetic field. In another embodiment, a sample preparation chamber or vessel is connected, directly or indirectly, to a waste chamber for collecting sample material which interferes with an amplification reaction (e.g., cell pellet).
A cartridge-based thermocycler of the present disclosure can have any suitable starting volume, such as at least about 25 μL, at least about 30 μL, at least about 35 μL, at least about 40 μL, at least about 45 μL, at least about 50 μL, at least about 55 μL, at least about 60 μL, at least about 65 μL, at least about 70 μL, at least about 75 μL, at least about 80 μL, at least about 85 μL, at least about 90 μL, at least about 95 μL, at least about 100 μL, and the like. In some examples, a cartridge-based thermocycler has a starting volume of about 25 μL, 30 μL, 35 μL, 40 μL, 45 μL, 50 μL, 55 μL, 60 μL, 65 μL, 70 μL, 75 μL, 80 μL, 85 μL, 90 μL, 95 μL, 100 μL or more. In one embodiment, one or more chambers of a cartridge has a non-compressed volume capacity of at least about 10 μL, at least about 15 μL, at least about 25 μL, at least about 30 μL, at least about 35 μL, at least about 40 μL, at least about 45 μL, at least about 50 μL, at least about 55 μL, at least about 60 μL, at least about 65 μL, at least about 70 μL, at least about 75 μL, at least about 80 μL, at least about 85 μL, at least about 90 μL, at least about 95 μL, at least about 100 μL, and the like. In another embodiment, one or more chambers of a cartridge has a non-compressed volume capacity of at least about 50 μL, at least about 100 μL, at least about 150 μL, at least about 200 μL, at least about 250 μL, at least about 500 μL, and the like. In one embodiment, one or more chambers of a cartridge has a compressed volume of less than about 100 μL, less than about 50 μL, less than about 40 μL, less than about 30 μL, less than about 20 μL, less than about 10 μL, or less than about 5 μL. The connecting channel disposed between two chambers has a volume, for example, of about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or 20% of the total fluid volume of the two chambers. For example, from about 1 μL to about 50 μL.
A cartridge-based thermocycler of the present disclosure can have a product rate of at least about 10 μL° C./second, at least about 25 μL° C./second, at least about 50 μL° C./second, at least about 75 μL° C./second, at least about 100 μL° C./second, at least about 150 μL° C./second, at least about 200 μL° C./second, at least about 250 μL° C./second, at least about 300 μL° C./second, at least about 325 μL° C./second, at least about 350 μL° C./second, at least about 375 μL° C./second, at least about 400 μL° C./second, at least about 425 μL° C./second, at least about 450 μL° C./second, at least about 500 μL° C./second, at least about 550 μL° C./second, at least about 600 μL° C./second, at least about 650 μL° C./second, at least about 700 μL° C./second, and the like. In some examples, a cartridge-based thermocycler has a product rate of about 10 μL° C./second, about 25 μL° C./second, about 50 μL° C./second, about 75 μL° C./second, about 100 μL° C./second, about 150 μL° C./second, about 200 μL° C./second, about 250 μL° C./second, about 300 μL° C./second, about 325 μL° C./second, about 350 μL° C./second, about 375 μL° C./second, about 400 μL° C./second, about 425 μL° C./second, about 450 μL° C./second, about 500 μL° C./second, about 550 μL° C./second, about 600 μL° C./second, about 650 μL° C./second, about 700 μL° C./second, or more. In one example, a starting volume of 50 μL with a heating or cooling rate of about 35° C. In 5 seconds is used. In this example, a product rate of about 350 μL° C./second is achieved. In some examples, a cartridge-based thermocycler can have a product rate within a range of about 10-700 μL° C./second, about 25-700 μL° C./second, about 100-700 μL° C./second, about 10-450 μL° C./second, about 25-450 μL° C./second, about 100-450 μL° C./second, about 300-400 μL° C./second, and the like. In some examples, a cartridge-based thermocycler can have a product rate within a sub-range. For example, the sub-range can be about (or at least about): 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more of a range (e.g., a range of about 10-700 μL° C./second, about 25-700 μL° C./second, about 100-700 μL° C./second, about 10-450 μL° C./second, about 25-450 μL° C./second, about 100-450 μL° C./second, about 300-400 μL° C./second, and the like). In some cases, the sub-range can comprise a lower portion of a range, an upper portion of a range, or an interior portion of a range. In some cases, the sub-range can have a width of at least about 0.01 μL° C./second, at least about 0.1 μL° C./second, at least about 1 μL° C./second, at least about 2 μL° C./second, at least about 5 μL° C./second, at least about 10 μL° C./second, at least about 20 μL° C./second, at least about 50 μL° C./second, at least about 100 μL° C./second, at least about 150 μL° C./second, at least about 200 μL° C./second, at least about 250 μL° C./second, and the like.
A cartridge-based thermocycler having a suitable starting volume can have a cycle time of less than about 20 seconds, less than about 15 seconds, less than about 12 seconds, less than about 11 seconds, less than about 10 seconds, less than about 9 seconds, less than about 8 seconds, less than about 7 seconds, less than about 6 seconds, less than about 5 seconds, less than about 4 seconds, and the like. In some examples, a cartridge-based thermocycler has a cycle time of about 12 seconds, about 11 seconds, about 10 seconds, about 9 seconds, about 8 seconds, about 7 seconds, about 6 seconds, about 5 seconds, about 4 seconds, or less.
The PCR chambers 4 and 5 can be coupled to one or more other chambers in some implementations. In an example, the disposable cartridge can be formed with three chambers. An additional or auxiliary chamber (not shown) can have nominal dimensions of about 12 mm in diameter and about 0.5 mm in height. In some examples, the auxiliary chamber can be a pre-chamber connected, permanently or temporarily (e.g., before being sealed off), to one or more PCR chambers of the disclosure. The auxiliary chamber can be capped by a thin flexible membrane material. The auxiliary chamber (also “blistered” chamber herein) can contain lyophilized reagents of Lysozyme and Proteinase-K stored in dry (e.g., powder) form. The auxiliary chamber may or may not be heated (e.g., by a heater on the durable instrument). In one example, a heater on a surface of the auxiliary chamber (e.g., on a back side of the auxiliary chamber) can apply heating needed for heat activation in the auxiliary chamber. The membrane can be blistered into the volume of the auxiliary chamber to move fluid to the next series of chambers representing the PCR thermocycling stage (e.g., chambers 4 and 5). The blistering can be done, for example, by an external actuator (e.g., an actuator on the durable instrument). In some cases, the actuator can execute minute movements (e.g., movements of about 0.1 mm) to mix the contents of the auxiliary chamber. The auxiliary chamber can be compressed by an actuator to move fluids to downstream processes. For example, the contents of the auxiliary chamber can be pushed out by the actuator deforming the blisterable membrane into the hot chamber (e.g., chamber 5) in the thermocycling stage. In some examples, the cartridge can comprise a valve that seals the contents (e.g., the sample fluid) in the hot thermocycling chamber. In one embodiment, the blistered chamber comprises reagents useful for performing a nucleic acid-based amplification reaction and/or detection of nucleic acid amplification products. Exemplary reagents include, without limitation, a hybridization oligonucleotide (e.g., probe, primers), ions and buffers. In one example, the blistered chamber comprises reagents for sample preparation. In another example, the blistered chamber comprises lyophilized or otherwise dried reagents.
In some examples, the contents can be sealed in the thermocycling chambers (e.g., chambers 4 and 5) via one or more pinch or clamp points, described in greater detail elsewhere herein. The pinch points can be pinched by, for example, one or more components (e.g., actuators or pistons) on the durable instrument. The pinch points can be clamped. In some cases, one or more valves are used (e.g., to control fluid and/or gas flow, such as to close and/or open channels to chambers). In some cases, the valve can be used instead of the pinch point. In some cases, the valve can be used in combination with the pinch point. In some cases, one or more valves can be combined with one or more pinch points.
The hot (thermocycling) chamber can be heated (e.g., maintained at about 95° C.) by an external thin film heater. Upon receiving the sample fluid from the auxiliary chamber, the contents of the hot chamber can be elevated in temperature for a given period of time (e.g., 95° C. for about 1 minute). This can inactivate the Proteinase-K and further lyse the cell walls of bacteria not lysed by the Lysosyme, thereby releasing DNA sample in the sample fluid from cell nuclei and disabling inhibitory factors to PCR. An actuator can be used to compress the hot chamber to move or push the sample fluid (e.g., contents of chamber 5) to the cold chamber (e.g., chamber 4) in the thermocycling stage.
The cold (thermocycling) chamber may or may not be heated (e.g., maintained at about 65° C.). Lyophilized “Master Mix” reagents including primers and TaqMan® probes can be stored in the cold chamber (e.g., maintained at about 65° C.). After mixing with the Master Mix, the sample fluid can be ready for thermocycling. An actuator can be used to compress the cold chamber to move or push the sample fluid back to the hot chamber to begin the thermocycling processes of the disclosure.
Thus, cartridge-based rapid thermocyclers having one or more auxiliary chambers can be provided. The auxiliary chambers can be used, for example, for filling, emptying or regulation of sample fluid in the PCR chambers. In an example, an auxiliary chamber can be used for pre-PCR preparation of the sample.
Laminated Disposable Cartridge
In some implementations, the cartridge comprising the chambers can have a laminate construction. The laminated cartridge can be disposable. For example, the laminated cartridge can be provided as a disposable element of a low-cost PCR system. In some cases, the laminated cartridge can be used strictly for PCR without addressing pre-PCR preparation of the sample. Alternatively, at least a portion of pre-PCR preparation can be provided on the laminated cartridge. Cartridges of the disclosure, including laminated cartridges, can be used in concert with mechanical actuation for moving a fluid from one chamber to another. The fluid in each chamber can be rapidly brought to desired temperatures for PCR (e.g., within 5 seconds). In some examples, each chamber can be held at a given PCR temperature (e.g., 95° C. or 65° C.) using fixed-temperature heater blocks. Other examples of heating configurations are described in greater detail elsewhere herein. Further, the cartridges enable the fluid sample to be optically interrogated for a fluorescence signal. Low-cost, disposable materials can be used to construct robust cartridges that can resist high pressures of PCR. Any aspects of the disclosure described in relation to laminated cartridges equally applies to other cartridges of the disclosure at least in some configurations.
The PSA layers can each have a given thickness. The thickness of the PSAs (e.g., combined thickness of the PSA layers) can define internal volumes of the PCR chambers 4 and 5. For example, the membranes 31 and 32 can form upper and lower surfaces, respectively, of each chamber, and the PSAs can form side walls of each chamber having a height corresponding to the combined thickness of the PSAs. In some cases, additional layered sheets (e.g., plastic layers) can be provided in combination with the PSAs. For example, additional plastic layers can be added to increase the fluid holding volumes of the chambers. In some cases, the volumes of the chambers can be identical. In other cases, the volumes of the chambers can differ.
The laminated cartridge can be heated on one or more surfaces. For example, at least one of the membranes 31, 32 (e.g., bottom membrane 32) can be positioned adjacent to heaters or adjacent to heater blocks (not shown) and formed of a thermally conductive material (e.g., polyimide, or polyester) configured for efficient heat transfer such that fluid that enters each chamber is rapidly equilibrated at a desired temperature.
The device geometry can be configured for efficient heat transfer and cost by changing thicknesses of the layered sheets or membranes 31 and 32 (e.g., thicknesses of the plastic). For example, a thinner plastic layer which is less durable provides improved heat transfer rates to the chambers. Further, the device geometry can be configured for efficient heat transfer and cost by changing heights and diameters of the PCR chambers. As described above, heights of the PCR chambers can be changed, for example, by changing the number and thickness of individual laminate layers that make up the sides of each chamber. The diameters of the PCR chambers can be changed by, for example, providing PSA layers with cutouts of different diameters. In one example, as shown in
In some implementations, one or more of the materials comprising the laminate layers of the cartridge can have hydrophilic properties. For example, plastic materials (e.g., plastic used to form one or more of the membranes) can have hydrophilic properties. The hydrophilic nature of the materials can provide various advantages for cartridge operation. For example, cartridge chambers (and/or fluid flow paths) having hydrophilic surfaces can be filled without leaving behind small trapped air or vapor bubbles. Such bubbles can become nucleation sites for larger air or vapor bubbles as the cartridge is heated for PCR. In some cases, this can lead to lower PCR efficiency. In some cases, the amount of air or vapor bubbles trapped during filling can be decreased by using cartridges with chambers (and/or fluid flow paths) having hydrophilic properties. Further, bubble formation can cause signal dropouts during in the detection system (e.g., during optical detection). Hydrophilic properties can be used in concert with the previously described shaped chambers and/or shaped fluid flow paths to achieve desired fluid flow conditions during filling and cycling on the cartridge.
Further, the laminated cartridge can comprise portions configured for efficient stretching upon mechanical actuation. For example, at least one of the membranes 31, 32 (e.g., top membrane 31) can be configured to stretch efficiently to allow the fluid to be moved from one chamber to another using mechanical actuation. In some cases, the membrane can stretch or “blister”.
The cartridge and chambers can be held against the heaters or the heater blocks by the pressures imposed by the actuators. For example, in a configuration where heating is provided by heater blocks adjacent the thermally conductive bottom 32, the cartridge can be held down against the heater blocks (e.g., heater blocks 12 and 13). Significant counter-pressure can be exerted by the actuator adjacent to the chamber filled with PCR fluid (i.e., the actuator located on the same side or portion of the cartridge as the chamber that is filled with PCR fluid).
The cartridge can be provided as a rigid structure. Alignment features 38 can be used to mechanically hold the individual laminate layers in place with respect to each other. The alignment features can include, but are not limited to, screws, nuts and bolts, heat stakes, pegs, adhesive filling, etc. In some implementations, an outer casing can be provided to allow easier handling and alignment (e.g., when inserting the cartridge into a durable instrument or analyzer). The outer casing can also provide features for filling the device and for valving the fluid to prevent leaking during PCR (e.g., using fill/vent ports and pinch points, as described elsewhere herein). The outer casing can be coupled to the laminate structure using, for example, the alignment features 38. In some cases, the outer casing can be coupled to the laminate structure without using the alignment features 38. For example, the outer casing can have flanges for gripping the laminate structure. The outer casing and the laminate structure can also be provided with mating features (clips, clasps, connectors, heat stakes, snap locks, etc.) for forming a secure mechanical connection. In some cases, the outer casing can comprise one or more secondary rigid structures or covers. For example, a first rigid cover 35 can be provided. In some examples, a second rigid cover 36 (e.g., as shown in
In some examples, a cardboard sheet (or a sheet or layer of any other suitable material, including disposable and/or biodegradable polymers, paper and pulp) can be coupled (e.g., bonded to, snapped onto, clipped onto, etc.) to the laminated structure for support. In some cases, the cardboard sheet can be formed as front and/or back covers. In other cases, the cardboard sheet can be shaped differently from the laminated cartridge. For example, the cardboard sheet can be rectangular and support a laminated structure with a more complex shape (e.g., as shown in
The laminated cartridge can comprise portions configured for transmitting optical signals. For example, at least one of the membranes 31, 32 (e.g., top membrane 31) can be positioned adjacent to optical excitation device(s) and detector(s) and formed of an optically transparent or clear material configured for transmitting optical signals 40 incoming to and outgoing from the sample. For example, an optically clear top membrane 31 can be used to transmit light from a light source to the sample (e.g., optical excitation) and to transmit light from the sample to a detector or readout (e.g., fluorescence emission).
In some implementations, the sample fluid can be optically detected in one or more of the PCR chambers (e.g., chambers 4 and 5). For example, fluorescence excitation and readout of the fluid can be accomplished by providing an optically transparent layered sheet or membrane formed of a material that allows excitation and readout to be made directly in a PCR well (also “chamber” herein) through the sheet or membrane. For example, a plastic or polymeric material such as polyester or PET can be used as the optically transparent material. In some cases, one or more laminate layers (e.g., the layered sheet or membrane, covers, etc.) can be partially formed from an optically transparent material (e.g., see
In other implementations, the sample fluid can be optically detected outside of the chamber(s), such as, for example, within any of the fluid flow paths (e.g., see
In yet other implementations, combinations of the above configurations can be used. For example, an optically transparent layer is useful to interrogate the fluid in the separate chamber without the need for a separate optical window (e.g., enabling a substantially flat form factor).
With continued reference to
In this example, a secondary rigid outer structure 35 and an alignment fixture 48 (e.g., for assembly/manufacturing) can be bonded with PSA. The secondary rigid outer structure 35 can serve as a front cover. In this example, a rigid bottom cover is not provided as the bottom of the laminate cartridge is placed directly onto heater block(s). The alignment fixture 48 may or may not serve as a (protective) bottom cover. In some examples, the positions of the rigid cover 35 and the alignment fixture 48 can be reversed (e.g., depending on which cartridge surface(s) are heated). In some examples, the rigid cover 35 can be substituted by an alignment fixture or removed altogether (e.g., to enable two-sided heating). In some examples, the alignment fixture 48 is not provided. PSA layer 41 can be used between the front cover 35 and the front membrane 31. A PSA layer 42 can be used between the alignment fixture 48 and the back membrane 32. In other examples, the PSA layers can be bonded using other techniques known in the art, as described elsewhere herein.
With continued reference to
The cartridge laminate layers can comprise one or more pinch points 46 with portions 46a, 46b and 46c provided, for example, on the laminate layers 35, 41 and 33, 34, respectively. Pinch points can be provided for a subset of cartridge chambers, or for all cartridge chambers (e.g., both of the chambers 4 and 5). Each pinch point 46 can be used to seal a corresponding chamber (e.g., after completion of fluid filling, fluid withdrawal, gas or fluid venting, etc.). The sealing can be permanent or reversible. In an example, one of the chambers can be sealed after filling, while another one of the chambers can be periodically vented. Prior to pinching or compression (e.g., by an actuator on a durable instrument), the pinch points on the chambers 4 and/or 5 can provide fluid communication between the chambers and the fill/vent ports 45 via the channels 7 and/or 8, respectively. The pinch points can also provide fluid communication with one or more other chambers (e.g., a pre-PCR preparation chamber, filter chamber, waste chamber, etc.) or external or internal tubing instead of, or in addition to the fill/vent ports 45. In some examples, more than one pinch point can be provided per chamber to enable closing of fluid connections with different cartridge or external components. In some implementations, pinching or compression of the pinch point can be enabled from top and/or bottom surfaces of the cartridge. For example, the pinch point can be compressed through one or more laminate layers (e.g., from the top cover 35 to the combined PSA layers 33, 34, from the alignment fixture 48 to the combined PSA layers 33, 34, or both). The pinch point can be pinched or compressed by locating the cartridge adjacent to one or more actuators. In some examples, the actuator(s) can pinch or compress the pinch point(s) from a top surface of the cartridge, from a bottom surface of the cartridge, or both.
In configurations comprising the cuvette, the size and/or shape of the optically interrogated volume enables adequate optical detection. In one embodiment, the optically interrogated volume is configured to decrease or minimize its contribution to dead volume of PCR (e.g., fluid volume that is not brought to temperature during any one PCR cycle). In some examples, the interrogated volume outside of one or more PCR chambers (e.g., outside of a heated PCR chamber) can be less than about 5% or less than about 10% of the total PCR fluid volume in the cartridge.
The source path can be affected and/or guided by optical components in the optical window 43 and/or the cartridge C in order to improve utilization of the excitation light and enhance transmission of light into the chamber 44. Further, the source path can be affected and/or guided by optical components in the optical window 43 and/or the cartridge C in order to direct the excitation light 51, 53 and 54 away from the detection direction 52. In some implementations, the optical window 43 can comprise light guiding elements such as, for example, prisms, lenses, or Fresnel lenses. For example, the optical window can comprise a prism 55 (e.g., a prism formed from a cyclo-olefin copolymer or other optically suitable material can be bonded to a top film of the optical window 43 or to a top film of the cartridge C). In some implementations, optical surfaces (e.g., surfaces facing the source path or a portion of the source path) can include anti-reflective coatings to help transmit the excitation light to the interrogation volume or sample channel (e.g., chamber 44, or one or more PCR chambers). In some implementations, foils 56 and 57 (e.g., light-blocking foils) can be used on one or more surfaces (e.g., surfaces of the cartridge directed toward the excitation light 51). Further, in some implementations, optical surfaces that allow scattered excitation light into the detection path (e.g., detection path 52) can be coated or blocked using foil, paint or other structures. For example, black-painted surfaces 58 can be provided on one or more interfaces of the optical plate or alignment fixture 48 (e.g., a cyclo-olefin copolymer or other optically suitable material can be bonded to a bottom (back) surface or film of the cartridge C) and/or on one or more interfaces of the prism 55. Light-directing features (e.g., lens or prism) and features to block stray light from the excitation source (e.g., foil or coatings) can be used separately or in combination (e.g., synergistically combined).
In an example, a nominal sample volume of 60 μL is contained within cartridge chambers with a total (combined) internal volume of about 60 μL. Each of the chambers 4 and 5 can have an undeformed internal volume of about 30 μL with a height (also “reduced sample volume height” herein) of about 250 μm. Upon actuation, one of the chambers (i.e., the chamber on the actuated side) is compressed and deformed (e.g., to a fraction of its undeformed internal volume). The sample volume is transferred to the other chamber, which is expanded and deformed. The deformed internal volume of this chamber can be about 60 μL (e.g., same as the sample volume). Upon subsequent actuation, the chamber that was previously expanded is compressed, the chamber that was previously compressed is expanded, and the situation is reversed. In some examples, the lower the height of the chamber, the larger the area that the sample volume can be spread out over, leading to enhanced heat transfer rates. For example, large values of surface area to height or surface area to volume ratios of the chambers can lead to increased heat transfer rates, and consequently decreased ramp times. In some examples, the height of one or more of the chambers is less than about 500 μm, less than about 400 μm, less than about 300 μm, less than about 250 μm, less than about 200 μm, and the like.
Laminate layers (e.g., layered sheets or membranes, PSAs, etc.) of the disclosure can have a given thickness. Laminate layers can have different thicknesses. In some cases, one or more laminate layers can have the same thickness. For example, PSA layers can have a first thickness and membranes can have a second thickness. In some cases, laminate layers can have the same thicknesses. In some implementations, a subset of the laminate layers can a thickness based on required mechanical integrity. For example, laminate layers that are exposed to heating may need to exhibit a higher mechanical integrity (e.g., coupled to heat resistance) than laminate layers that are not exposed to heating. In another example, laminate layers that are exposed to a higher degree of stretching and/or compression may need to exhibit a higher mechanical integrity than laminate layers that experience less stress (e.g., membranes may need to withstand a higher mechanical stress than PSAs). Further, the thickness of each laminate layer can vary across the area of the laminate layer. For example, the laminate layer can be thicker in an area that is exposed to a higher degree of stress (e.g., chamber pressure, tension, compression strength). In another example, the laminate layer thickness can be reduced in areas where optical detection, heat transfer, pinching, filling, extraction, venting and/or other cartridge manipulations are performed. As described elsewhere herein, laminate layer thickness can further be used to define chamber volume. For example, the thickness of one or more PSA layers can be larger than the thickness of one or more membranes in situations where thicker PSA layers are used to implement chambers with larger internal volume(s). In another example, membrane thickness is adjusted to achieve a given mechanical integrity and/or heat transfer performance, while PSA thickness is adjusted to achieve a given internal volume of chambers, or vice versa. Further, membrane thickness and/or PSA thickness can be adjusted to achieve a given mechanical integrity, a given heat transfer performance, a given internal volume of chambers, or any combination thereof.
In some examples, a laminate layer, or a portion thereof, can have a thickness of at least about 10 μm, at least about 20 μm, at least about 30 μm, at least about 40 μm, at least about 50 μm, at least about 60 μm, at least about 70 μm, at least about 80 μm, at least about 90 μm, at least about 100 μm, at least about 110 μm, at least about 120 μm, at least about 130 μm, at least about 140 μm, at least about 150 μm, at least about 160 μm, at least about 170 μm, at least about 180 μm, at least about 190 μm, at least about 200 μm, and the like. In some examples, a laminate layer of the disclosure can have a thickness of at less than about 10 μm, less than about 20 μm, less than about 30 μm, less than about 40 μm, less than about 50 μm, less than about 60 μm, less than about 70 μm, less than about 80 μm, less than about 90 μm, less than about 100 μm, less than about 110 μm, less than about 120 μm, less than about 130 μm, less than about 140 μm, less than about 150 μm, less than about 160 μm, less than about 170 μm, less than about 180 μm, less than about 190 μm, less than about 200 μm, and the like. In some examples, a laminate layer has a thickness of about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 35 μm, about 40 μm, about 45 μm, about 50 μm, about 55 μm, about 60 μm, about 65 μm, about 70 μm, about 75 μm, about 80 μm, about 90 μm, about 100 μm, about 110 μm, about 120 μm, about 130 μm, about 140 μm, about 150 μm, about 160 μm, about 170 μm, about 180 μm, about 190 μm, about 200 μm, or more. In an example, a membrane formed of a heat conductive material can have a thickness of about 30-70 μm or about 45-55 μm, while a PSA layer can have a thickness of about 100-150 μm or about 125-130 μm.
Multichamber Cartridges
In one aspect, provided herein are multichamber cartridges for use in a thermocycling reaction. In exemplary embodiments, a multichamber cartridge is a component of a thermocycler or cartridge-based system described herein. In one embodiment, a multichamber cartridge comprises a disposable portion of a thermocycler system. A thermocycler system, such as previously described herein accommodates one or more multichamber cartridges for performing simultaneous thermocycling reactions. In some embodiments, the multichamber cartridge comprises a first chamber for holding a fluid at a first average temperature and a second chamber for holding the fluid at a second average temperature. The second chamber is in fluid communication with the first chamber, wherein the fluid is transferred between the first chamber and the second chamber to achieve a transition from the first average temperature to substantially the second average temperature or vice versa. The first chamber and the second chamber are in fluid connection via a connecting channel. In an exemplary embodiment, a multichamber cartridge is a disposable as described previously herein, for example, a laminated disposable cartridge, and vice versa. In another embodiment, a cartridge or thermocycler as previously described further comprises or is operably connected to one or more components or elements of a multichamber cartridge as described below, for example, a buffer solution tube or blistered chamber.
An average temperature includes any temperature within 5° C. of the set temperature, for example, an average temperature for a reaction in a hot chamber set at 95° C. has a temperature from about 90° C. to about 100° C. In another embodiment, an average temperature includes any temperature within 3° C. of the set temperature, for example, an average temperature for a reaction in a hot chamber set at 95° C. has a temperature from about 92° C. to about 98° C. In another embodiment, an average temperature includes any temperature within 2° C. of the set temperature, for example, an average temperature for a reaction in a hot chamber set at 95° C. has a temperature from about 93° C. to about 97° C. In another embodiment, an average temperature includes any temperature within 1° C. of the set temperature, for example, an average temperature for a reaction in a hot chamber set at 95° C. has a temperature from about 94° C. to about 96° C. In certain instances, the temperature of a heater fluctuates between average temperature values during a thermocycling reaction. Alternatively, the temperature of a heater does not fluctuate temperature during a thermocycling reaction. A substantially average temperature includes a temperature within 5° C., 4° C., 3° C., 2° C., 1° C. or 0.5° C. of the average temperature. The average temperature includes the temperature set in a thermocycling reaction, the temperature of a heating element (e.g., heater as described herein), the temperature of a fluid in chamber, and any combination thereof.
In one embodiment, the multichamber cartridge comprises a third chamber for holding a fluid at a third average temperature in fluid communication, directly or indirectly, with the first chamber, the second chamber, or both the first and second chambers. In another embodiment, a multichamber cartridge comprises a fourth chamber for holding a fluid at a fourth average temperature. In yet another embodiment, a multichamber cartridge comprises a fifth, sixth, seventh, eighth, ninth or tenth chamber for holding a fluid at a fifth, sixth, seventh, eighth, ninth or tenth average temperature, respectively. In various implementations, the third chamber, fourth chamber, fifth chamber, sixth chamber, seventh chamber, eighth chamber, ninth chamber, tenth chamber, or any combination thereof is an auxiliary chamber. In one example, the auxiliary chamber is a blistered chamber. In alternative implementations, the third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or any combination thereof is not held at a fixed average temperature.
In one instance, the first chamber, second chamber, third chamber, fourth chamber, fifth chamber, sixth chamber, seventh chamber, eighth chamber, ninth chamber, tenth chamber, or any combination thereof is held at an average temperature of between about 90° C. and about 110° C. for a given time during a thermocycling reaction. In one instance, the first chamber, second chamber, third chamber, fourth chamber, fifth chamber, sixth chamber, seventh chamber, eighth chamber, ninth chamber, tenth chamber, or any combination thereof is held at an average temperature suitable for denaturing nucleic acid molecules for a given time during a thermocycling reaction. In one instance, the first chamber, second chamber, third chamber, fourth chamber, fifth chamber, sixth chamber, seventh chamber, eighth chamber, ninth chamber, tenth chamber, or any combination thereof is held at an average temperature of between about 40° C. and about 75° C. for a given time during a thermocycling reaction. In one instance, the first chamber, second chamber, third chamber, fourth chamber, fifth chamber, sixth chamber, seventh chamber, eighth chamber, ninth chamber, tenth chamber, or any combination thereof is held at an average temperature suitable for nucleic acid annealing for a given time during a thermocycling reaction. In one instance, the first chamber, second chamber, third chamber, fourth chamber, fifth chamber, sixth chamber, seventh chamber, eighth chamber, ninth chamber, tenth chamber, or any combination thereof is held at an average temperature of between about 60° C. and about 80° C. for a given time during a thermocycling reaction. In one instance, the first chamber, second chamber, third chamber, fourth chamber, fifth chamber, sixth chamber, seventh chamber, eighth chamber, ninth chamber, tenth chamber, or any combination thereof is held at an average temperature suitable for nucleic acid extension for a given time during a thermocycling reaction. In one instance, the first chamber, second chamber, third chamber, fourth chamber, fifth chamber, sixth chamber, seventh chamber, eighth chamber, ninth chamber, tenth chamber, or any combination thereof is held at an average temperature suitable for nucleic acid digestion (e.g., with restriction enzymes) or ligation. In one instance, the first chamber, second chamber, third chamber, fourth chamber, fifth chamber, sixth chamber, seventh chamber, eighth chamber, ninth chamber, tenth chamber, or any combination thereof is held at an average temperature suitable for temporarily storing or cooling nucleic acid molecules, for example from about 2° C. to about 25° C.
In one embodiment, a multichamber cartridge is configured to receive a sample from a swab collection tube. In one implementation, the swab collection tube is a removable component of a multichamber cartridge. A swab collection tube retains a sample, optionally collected on a swab. For example, a sample is collected from a subject or environment and placed in a sample collection tube for storage. The sample can then be transferred to a multichamber cartridge prior to a thermocycling reaction. In one embodiment, the sample comprises nucleic acids to be amplified in an amplification reaction. In addition to a sample, the swab collection tube is configured to retain a swab solution, which includes reagents for preserving a sample, such as a biological sample, and includes, without limitation, buffer agents and salts. In another example, a swab collection tube comprises processing reagents. In one embodiment, the swab collection tube is fitted with a swab plunger for delivering a sample solution to a chamber or other component of a multichamber cartridge. In one instance, the contents of a swab collection tube, or a portion thereof, are delivered to a chamber of the multichamber cartridge via a receiving tube. In another instance, a sample is processed in the swab collection tube. For example, a sample comprising whole blood is processed to separate serum, wherein the processing reagents in the sample collection tube comprise a polymer gel and a powdered glass clot activator.
In various aspects, a sample provided to a cartridge described herein comprises one or more analytes suitable for a thermocycling reaction. Exemplary analytes include nucleic acid molecules to be amplified during a thermocycling reaction. Samples include fluid and solid samples. The sample includes any appropriate material, with any suitable origin. For example, a sample includes, without limitation, a biomolecule, organelle, virus, cell, tissue, organ, and/or organism. A sample optionally is a biological sample, such as blood, urine, saliva, sweat, seminal fluid, tissue, amniotic fluid, cerebrospinal fluid, synovial fluid, tears, fecal matter, and/or mucous, among others. A sample optionally is an environmental sample, such as a sample from air, water, or soil. In one embodiment, a sample is aqueous and optionally comprises buffering agents, inorganic salts, and/or other components known for assay solutions. Suitable samples include compounds, mixtures, surfaces, solutions, emulsions, suspensions, cell cultures, fermentation cultures, cells, tissues, secretions, and/or derivatives and/or extracts thereof. A sample includes food products. In some instances, a sample is provided to the cartridge in a processed form altered from its original state. For example, it may be necessary to lyse or permeabilize cells to release nucleic acids. Such methods include chemical (e.g., Lysozyme), mechanical (e.g., sonication), thermal, or a combination thereof. As another example, a sample comprising a pathogenic organism is chemically or thermally inactivated. In some instances, analytes (e.g., nucleic acids) of a processed sample are isolated or separated in one or more tubes or chambers of the cartridge.
In one embodiment, a multichamber cartridge comprises a receiving tube for receiving a sample. In one implementation, the sample is provided in whole or in part from a swab collection tube. In another example, a sample (optionally processed) is provided to the receiving tube directly via an opening, for example, a fill port, by any means suitable for transferring a liquid or semi-liquid solution, e.g., syringe, pipette or plunger. In one embodiment, the receiving tube is a disposable and/or removable component of a thermocycler.
In one embodiment, a multichamber cartridge comprises one or more buffer solution tubes, wherein each buffer solution tube is configured to hold one or more buffers or aqueous solutions. In one embodiment, a multichamber cartridge comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more buffer solution tubes. In an exemplary embodiment, a multichamber cartridge comprises 3 buffer solution tubes. In one instance, the multichamber cartridge is formulated to hold one or more buffers in the one or more buffer solution tubes, for example, the multichamber cartridge is manufactured with buffer solution(s) stored in the tube(s). In one embodiment, the buffers are supplied in a cartridge as aqueous solutions or as dehydrated pellets to be reconstituted with an aqueous solution. In another instance, the multichamber cartridge is supplied with buffers by a thermocycler end-user, wherein the buffer components are optimized for a specific thermocycling reaction. A buffer or aqueous solution comprise any components useful for carrying out a thermocycling reaction, e.g., a nucleic acid amplification reaction. Suitable components include, without limitation, primers, probes, polymerases, nucleotides, divalent cations, and monovalent cations. In one embodiment, a buffer solution tube holds volumes up to about 5 mL, up to about 4 mL, up to about 3 mL, up to about 2 mL, up to about 1 mL, up to about 0.5 mL, up to about 0.4 mL, up to about 0.3 mL, up to about 0.2 mL or up to about 0.1 mL. In one embodiment, one or more buffer solution tubes are disposable and/or removable components of a thermocycler.
In one embodiment, a multichamber cartridge comprises a means for delivering a buffer solution to a chamber of the cartridge. For example, a buffer solution is delivered to a chamber of the cartridge by application of a plunger. In the instances wherein a multichamber cartridge comprises a plurality of buffer solution tubes, one or more buffer solutions are delivered to one or more chambers via a rotating plunger. In one embodiment, the plunger is a disposable and/or removable component of a thermocycler.
In one embodiment, a multichamber cartridge comprises a rotating filter membrane comprising a plurality of channels in connection with one or more tubes or chambers of the cartridge, wherein the plurality of channels are opened or closed by rotating the rotating filter membrane. In one embodiment, the rotating filter membrane is in fluid connection with a receiving tube. In one embodiment, the rotating filter membrane is in fluid connection with one or more buffer solution tubes. In one embodiment, the rotating filter membrane is in fluid connection with a waste chamber. In another embodiment, the rotating filter member is in fluid connection with a blistered chamber. In another embodiment, the rotating filter membrane is in fluid connection with the first chamber or cold chamber. In yet another embodiment, the rotating filter membrane is in fluid connection with the second or hot chamber. In further embodiments, the rotating filter membrane is in fluid connection with a third, fourth, fifth, sixth, seventh, eighth, ninth, tenth chamber or any combination thereof. In one embodiment, the rotating filter membrane is a disposable and/or removable component of a thermocycler.
In one embodiment, a multichamber cartridge comprises a waste chamber or alternatively, a waste tube. The waste chamber holds waste from one or more tubes and/or one or more chambers of a multichamber cartridge. In some embodiments, the waste chamber holds volumes up to about 10 mL, up to about 8 mL, up to about 7 mL, up to about 6 mL, up to about 5 mL, up to about 4 mL, up to about 3 mL, up to about 2 mL, up to about 1 mL, or up to about 0.5 mL. In one embodiment, the waste chamber is a disposable and/or removable component of a thermocycler.
In one embodiment, a multichamber cartridge comprises a blistered chamber, for example, a blistered chamber as previously described. In one embodiment, the blistered chamber is in fluid connection with a rotating filter membrane. In another embodiment, the blistered chamber is in fluid connection with a first or cold chamber. In another embodiment, the blistered chamber is in fluid connection with a second or hot chamber. In another embodiment, the blistered chamber is in fluid connection with a third, fourth, fifth, sixth, seventh, eighth, ninth, tenth chamber or any combination thereof. In some implementation, the blistered chamber is compressed by an actuator to move contents to other chambers of the cartridge, for example, the first or second chambers. In one instance, the actuator is a component of a thermocycler provided herein. In one embodiment, the blistered chamber is a disposable and/or removable component of a thermocycler. The blistered chamber, in many instances, comprises reagents useful for sample preparation and/or performing a thermocycling reaction. Such reagents are manufactured with the cartridge or added by an end-user prior to performing a thermocycling reaction. Suitable reagents include, without limitation, Lysozyme and Proteinase K. In one embodiment, the reagents are formulated as a solution or a powder. In one embodiment, one or more reagents of the blistered chamber are activated by a heater in a heat activation step. In an additional embodiment, the blister chamber is in contact with a heater.
In an exemplary embodiment, a fluid comprising a sample is moved from one chamber to another, e.g., between a first and second chamber, by deforming one chamber with pressure from one or more actuators as previously described.
In one embodiment, a multichamber cartridge comprises a window or cuvette to view a fluid in the cartridge. In an exemplary embodiment, the window is an optical viewing window useful for fluorescent detection. The optical viewing window is comprised of optically transparent material for receiving and transmitting light.
The chambers of the multichamber cartridge are of any size suitable for their respective functions in an amplification reaction. For example, any chamber of the multichamber cartridge holds a volume of solution (e.g., sample reaction solution, buffer solution, waste solution, blistered chamber solution) from about 5 μL to about 5 mL. Similarly, the tubes of the multichamber cartridge are of any size to accommodate volumes from about 5 μL to about 5 mL. In one embodiment, one or more tubes, chambers and/or other multichamber components are operably connected to or attached to the multichamber cartridge. In various implementations, any number of components, e.g., tube, chamber, are removable or non-removable components.
In one embodiment, one or more chambers or components of a cartridge provided herein is adapted for nucleic acid extraction, nucleic acid purification, nucleic acid detection and/or nucleic acid amplification.
In one embodiment, the multichamber cartridge is a disposable portion of a thermocycler. In another embodiment, the multichamber cartridge is useful with a thermocycler described herein. In another embodiment, the multichamber cartridge is a laminated disposable cartridge.
In one embodiment, the multichamber cartridge comprises plastic injected polycarbonate material. In one embodiment, the multichamber cartridge comprises Kapton laminate. In another embodiment, the multichamber cartridge comprises PSA. In a further embodiment, the multichamber cartridge comprises PET laminate. Additional multichamber cartridge materials include, without limitation, cardboard, plastic and paper.
In one embodiment, one or more components of the multichamber cartridge are labeled. For example, a label provides information that is readable to a human or machine to provide information relating to a sample. A label includes a scannable barcode.
In one aspect, fluid is transferred between one or more chambers of a cartridge provided herein and one or more chambers and/or cartridge components provided herein, by mechanical actuation. In other embodiments, fluid is transferred without using movable components of a cartridge and/or thermocycler. In some embodiments, fluid is transferred using magnetic means, for example, by using magnetic fluids or magnetic beads.
In various implementations, one or more chambers of the cartridges described herein are pre-loaded with reagents. Reagents include liquids, solids, gases or combinations thereof. In an additional embodiment, one or more chambers of the cartridge comprises at least one opening to allow for the addition or removal of a sample. In one embodiment, the opening is sealed or otherwise closed to maintain the sample in the chamber. In another or additional embodiments, a chamber is initially empty so as to serve, for example, as a waste, mixing and/or detection chamber prior to, during or after a thermocycling reaction. Reagents include those which are formulated as a pellet or tablet, or are lyophilized. In an example, reagents are useful for sample preparation (e.g., immobilization), amplification (e.g., primers), or detection (e.g., probes). In one embodiment, a solid reagent is re-suspended with a fluid, for example, one provided by an adjacent chamber or tube. In an additional embodiment, a chamber comprises cryoprotectants or preserving agents such as disaccharides (e.g., trehalose, sucrose).
In various implementation, one or more chambers of the cartridge are useful for processing amplified nucleic acids after completion of thermocycling. For example, a chamber comprises one or more reagents, either pre-loaded or provided by an end-user, for performing a restriction digest on amplified nucleic acids. In another or additional embodiment, a chamber comprises one or more reagents, either pre-loaded or provided by an end-user, for performing a ligation reaction.
A cartridge is loaded with a sample by manual, automated, or manual and automated methods. Sample loading methods include, without limitation, pipetting, injection, spotting, and syringe drawing.
An exemplary multichamber cartridge is provided in
The multichamber cartridge of
The multichamber cartridge of
In one embodiment, a rotating filter membrane 166 controls release of a sample from the receiving tube 163 to a blister chamber 168 and/or a waste chamber 167. In one embodiment, a rotating filter membrane 166 controls release of a buffer from one or more buffer tubes 165 to a blister chamber 168 and/or a waste chamber 167.
Cartridge-Based Thermocycler Methods
In one aspect, provided herein are cartridge-based thermocyclers and thermocycling systems comprising one or more cartridges. In one embodiment, a thermocycler described herein is configured to perform a thermocycling reaction with at least two cartridges at the same time. In one example, one cartridge comprises a reference sample and another cartridge comprises a test sample. For instance, in a diagnostic assay, a reference or control sample is amplified under the same conditions as a test sample.
The cartridge-based thermocyclers provided herein allow for the quantitative or qualitative detection of a target nucleic acid in a sample. For example, during a nucleic acid amplification reaction, a target component in a sample is detected when one or more detectably labeled probes hybridize to the target and to the amplification products thereof. In many instances, the detection of the target is indicative of a disease presence in the sample, for example, when the target is a nucleic acid from an infectious agent. In another instance, the expression level of a target nucleic acid in a sample is quantified during a PCR reaction. In some instances, expression level is indicative of a disease state or a correlation to a disease state. For example, differential expression of a nucleic acid expression product, e.g., RNA, as compared to a reference expression level, is indicative of a disease state.
In another aspect, provided herein are thermocycling systems useful for forensic applications, for example, in genetic fingerprinting.
In another aspect, provided herein are thermocycling systems useful for DNA sequencing.
In exemplary embodiments, the thermocycling systems provided herein can be employed to detect and/or quantify two or more different nucleic acids in a sample. For example, the nucleic acids can be quantified according to the rate at which they can be amplified detectably from the sample by an amplification reaction in which the nucleic acids are copied exponentially and/or linearly. Any suitable amplification approach can be used, including PCR. In some embodiments, probes for different nucleic acid targets in a sample are labeled with a different detectable label (e.g., fluorescent label). Hybridization of a probe to the target can produce a change in light emission from the detectable label. A suitable assay that can quantify nucleic acids according to the rate of change in light emission is exemplified by a TaqMan® assay (Applied Biosystems). The cartridges, thermocyclers, and systems provided herein are useful for such thermocycling reactions. Thermocycling reactions include nucleic acid amplification reactions. Such reactions include, without limitation, PCR, real-time PCR, allele-specific PCR, SNP genotyping, assembly PCR (e.g. nucleic acid synthesis), asymmetric PCR, helicase-dependent amplification, ligation mediated PCR, quantitative PCR, and reverse transcription PCR. In one embodiment, the cartridges, thermocyclers and systems provided herein are used for multiplex-PCR.
The detection and/or measurement of amplification products are performed at reaction completion or in real time (i.e., during reaction), where real time includes continuous or discontinuous measurement and/or detection. If the measurement of accumulated amplified product is performed after amplification is complete, the labeled probes can be added after the amplification reaction. Alternatively, probes are added to the reaction prior to or during the amplification reaction.
In another aspect, provided herein are cartridge-based thermocyclers for performing real-time PCR. Real-time PCR, in various implementations, is useful to simultaneously amplify and detect or quantify a nucleic acid molecule in a sample. In one embodiment, amplified nucleic acid molecules are detected using detectable dyes, e.g., fluorescent dyes, that intercalate with DNA. In another embodiment, amplified nucleic acid molecules are detected using nucleic acid probes comprising detectable labels. In one embodiment, a probe comprises a plurality of detectable labels. Detectable labels are naturally and/or artificially occurring. Naturally occurring labels include green fluorescent protein (GFP), phycobiliproteins, luciferase, and/or their many variations, among others. Artificially occurring labels include, for example, rhodamine, fluorescein, FAM™/SYBR® Green I, VIC®/JOE, NED™/TAMRA™/Cy3™, ROX™/Texas Red®, Cy5™ among others. Suitable natural and artificial labels are disclosed in the following publication, among others, which is incorporated herein by reference: Richard P. Haugland, Handbook of Fluorescent Probes and Research Chemicals (6th ed. 1996). In some embodiments, a fluorescently labeled probe is active only in the presence of a target molecule, for example, a specific nucleic acid sequence, so that a fluorescent response from a sample signifies the presence of the target molecule. In exemplary embodiments, a probe is a hybridization probe comprising an oligonucleotide which hybridizes to a target nucleic acid sequence that is complementary to the oligonucleotide probe sequence.
In some embodiments, a probe is a molecular beacon. A molecular beacon probe, as described herein, includes a single-stranded oligonucleotide in which the bases on the 3′ and 5′ ends are complementary, forming a stem. A molecular beacon probe forms a hairpin structure at temperatures at and below those used to anneal the oligonucleotide to a target. In some embodiments, the molecular beach probe forms a hairpin structure at temperatures below about 60° C. The double-helical stem of the hairpin brings a fluorophore (or other label) attached to the 5′ end of the probe in proximity to a quencher attached to the 3′ end of the probe. The probe does not fluoresce (or otherwise provide a signal) in this conformation. If a probe is heated above the temperature needed to melt the double stranded stem apart, or the probe hybridizes to a target nucleic acid that is complementary to the sequence within the single-strand loop of the probe, the fluorophore and the quencher are separated, and the fluorophore fluoresces in the resulting conformation. Therefore, in a series of nucleic acid amplification cycles the strength of the fluorescent signal increases in proportion to the amount of the molecular beacon that is hybridized to the target, when the signal is read at the annealing temperature. Molecular beacons of high specificity, having different loop sequences and conjugated to different fluorophores, can be selected in order to monitor increases in amplicons that differ by as little as one base.
During a real-time PCR reaction, fluorescence intensity is monitored in real time. A key element in the measurement is to identify the thermal cycle number at which the label emission intensities rise above background noise and starts to increase, preferably exponentially. This cycle number is called the threshold cycle, Ct. The Ct value is inversely proportional to the number of starting copies of the DNA sample in the original PCR solution. Knowing Ct, the quantity of the DNA to be detected in the sample can be determined.
In one aspect, provided herein are thermocycling systems useful for the identification and management of a disease state. For example, DNA fragments comprising a gene or expression product thereof can be amplified and detected using one or more detectably labeled probes as previously described. In one embodiment, a detectably labeled probe comprising a sequence indicative of a disease state comprises a distinct fluorophore which is detected using an optical detector. For example, a sequence indicative of a disease state comprises one or more mutations. In some embodiments, the presence of a sequence of nucleic acid is identified using a thermocycling system described herein. In one example, a nucleic acid sequence from an infectious disease agent (e.g., bacteria, virus) is present in a human or environmental sample. The nucleic acid sequence is amplified and detected by hybridization with a detectably labeled probe. In some embodiments, a plurality of dectably labeled probes are provided in an amplification reaction, wherein unique combinations of probes are indicative of a disease state, allowing for a multiplex reaction to be performed within one cartridge. In other embodiments, a plurality of cartridges are used in a thermocycling system provided herein.
In another aspect, provided herein is a method for monitoring a thermocycling reaction, the method comprising a) providing a thermocycler comprising a first chamber for holding fluid at a first average temperature and a second chamber for holding the fluid at a second average temperature, wherein the second chamber is in fluid communication with the first chamber, b) introducing a sample into either the first chamber or the second chamber, wherein the sample comprises a nucleic acid molecule and one or more detectably labeled probes configured to hybridize to the nucleic acid molecule; c) transferring the sample from the first chamber to the second chamber; and d) measuring a detectable signal emitting from the sample in response to a stimulus using an optical detector. In some embodiments, the detectable signal comprises both a signal correlating to nucleic acid amplification and a signal correlating to noise. In some instances, the signal correlating to nucleic acid amplification is indicative of a quantity of amplified nucleic acid in the sample. In some embodiments, the signal correlating to nucleic acid amplification is distinguishable from the signal correlating to noise.
A cartridge of a cartridge-based thermocycler comprises a four-layered laminated structure having two chambers in fluid connection via a connecting channel. One or both of the chambers is connected to one or more addition channels to allow for filling a chamber with fluid or extracting fluid from a chamber. The structure is manufactured with or without an optical window. If the structure is manufactured without the optical window, an optical detection signal can be read through a top layer of the structure, preferably over a chamber of the cartridge. The cartridge comprises a laminate layer having a 50.8 μm thick PET film, a laminate layer having a 127 μm thick 3M 96042 Double-Coated Silicone Adhesive layer, another laminate layer having a 127 μm thick 3M 96042 Double-Coated Silicone Adhesive layer, and a laminate layer having a 50.8 μm thick Kapton® MT film. The thickness of each chamber is 254 μM. A working example of this cartridge is shown in
A cartridge as described in Example 1 is part of a thermocycling system comprising a thermocycling instrument. The thermocycling instrument comprises two heater blocks, wherein one heater block provides heat at a first average temperature to the first chamber and the second heater block provides heat at a second average temperature to the second chamber. The thermocycling instrument comprises two actuators, wherein one actuator provides pressure to one chamber and the second actuator provides pressure to the second chamber, and wherein said pressure is sufficient to propel a fluid from one chamber into another chamber.
A 50 μL nucleic acid amplification reaction was prepared comprising 21.25 μL of 105 DNA/mL B. Atm, 25 μL TaqMan® Master Mix, 1.25 μL of 105 μM FAM probe, 1.25 μL of 36 μM B. Atro forward primer and 1.25 μL of 36 μM B. Atro reverse primer. The reaction mixture was added to a first chamber of the cartridge through a channel. The cartridge was placed in a slot of the thermocycling instrument and a thermocycling program was set. Thermocycling conditions were: 95° C. for 30 seconds; 55 cycles of 95° C. for 10 seconds and 60° C. for 10 seconds. During the thermocycling reaction, actuators of the instrument applied pressure alternatively to each chamber, propelling the reaction mixture from one chamber to another through a connecting channel, while each chamber was maintained at an average temperature by each heater. One chamber was maintained at an average temperature of 60° C. and the other chamber was maintained at an average temperature of 95° C.
The reaction was monitored in real-time by measuring fluorescence intensity as a function of cycle number. The fluorescence intensity data is shown in
This example describes a quantitative real-time RT-PCR assay for the detection of an infectious disease from a patient sample, in this instance serum. This assay targets a nucleic acid region specific in sequence for the disease, in this case a virus, and utilizes fluorescently labeled probes for detection. This assay is similarly performed utilizing a plurality of probes targeting additional infectious diseases in a multiplexed assay. Alternatively, this assay is performed for serotyping a disease by utilizing a plurality of probes targeting different serotypes of the disease. These optional multiplexed assays are performed in a single cartridge of a thermocycler described herein.
The real-time RT-PCR reaction is performed using a thermocycler described in Examples 1 and 2, which is operably attached to an optical detector, and a commercial qRT-PCR kit (SuperScript One-Step qRT-PCR, Life Technologies). The connecting channel of the cartridge has an optical window to allow for excitation light from the optical detector to reach the sample and to allow for emission light from the reaction mixture to reach the detector. Thus, during the thermocycling reaction, as the detectably labeled probe hybridizes to amplification products, the optical detector records fluorescence signals in real-time.
The real-time RT-PCR reaction mixture comprises a forward primer and reverse primer designed to amplify a target nucleic acid region of the virus. Nucleic acids are extracted from serum samples of a patient using the QIAamp Viral RNA Mini Kit (Qiagen) using recommended procedures. The extracted nucleic acids are added to the reaction mixture at concentrations between about 1 pg to about 1 μg total RNA. A TaqMan® probe is added to the final PCR reaction. The probe is added to the reaction via a blistered chamber or directly to the reaction mixture.
Thermocycling conditions are: 50° C. for 15 minutes (RT step); 95° C. for 2 minutes; 40 cycles of 95° C. for 2 seconds and 60° C. for 2 seconds. The total cycle time is less than about 25 minutes and the PCR time is less than about 10 minutes.
The reaction is monitored in real-time using an optical detector to detect fluorescence of the detectably labeled probe hybridized to amplified target nucleic acids.
A positive diagnosis of the infectious disease is considered when a sample has a Ct value less than about 35.
This diagnosis is performed as a point-of-care assay. As an example, the sample is whole blood which is processed in a sample processing cartridge prior to addition to the thermocycling cartridge. Alternatively, the sample is processed in one or more chambers of a thermocycling cartridge as a first step in a thermocycling reaction.
A disposable portion of a thermocycler is provided in the form of a single cartridge. The cartridge comprises at least two chambers connected by a channel to allow fluid to flow between the chambers. The chambers are constructed from suitable material to allow for compression. One or both chambers is connected, e.g., through a channel, to one or more ports, to allow for the addition or removal of a liquid, gas, solid or combination thereof. The cartridge is customizable with additional elements.
One additional element is a means to allow for the optical detection of a substance within the cartridge. This means includes an optical window located in a chamber or connecting channel. Another means is a cuvette connected by a fluid path to one or more chambers. The cartridge is configured for optical detection in real-time or at one or more time points during use.
Another additional element is a blistered chamber. The blistered chamber is similarly customizable to comprise reagents for use in a thermocycling reaction. Alternatively, the blistered chamber is supplied empty, allowing for an end-user to add reagents.
The cartridge is optionally provided with an instrument in a thermocycler system. The instrument is able to act on all or a portion of the cartridge and such actions are programmable. Such actions include moving a fluid between chambers, opening and closing channels between chambers, providing a barrier between chambers, heating or cooling a chamber, and any combination thereof. The instrument is configured to be provided with, or configured to be operably connected to, an optical detector.
It is to be understood that the terminology used herein is used for the purpose of describing specific embodiments, and is not intended to limit the scope of the present invention. It should be noted that as used herein, the singular forms of “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. In addition, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
While preferable embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
This application is a continuation of U.S. patent application Ser. No. 15/124,334, filed Sep. 7, 2016, which is national stage entry of International Patent Application No. PCT/US2015/019497, filed Mar. 9, 2015, which claims priority to U.S. Provisional Patent Application Ser. No. 61/950,769, filed Mar. 10, 2014, which applications are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3697227 | Goldstein et al. | Oct 1972 | A |
| 4710355 | Ushikubo et al. | Dec 1987 | A |
| 4889692 | Holtzman et al. | Dec 1989 | A |
| RE33858 | Gropper et al. | Mar 1992 | E |
| 5164159 | Hayashi et al. | Nov 1992 | A |
| 5229297 | Schnipelsky et al. | Jul 1993 | A |
| 5270183 | Corbett et al. | Dec 1993 | A |
| 5273905 | Muller et al. | Dec 1993 | A |
| 5405585 | Coassin et al. | Apr 1995 | A |
| 5429807 | Matson et al. | Jul 1995 | A |
| 5498392 | Wilding et al. | Mar 1996 | A |
| 5631165 | Chupp et al. | May 1997 | A |
| 5633168 | Glasscock et al. | May 1997 | A |
| 5660993 | Cathey et al. | Aug 1997 | A |
| 5726026 | Wilding et al. | Mar 1998 | A |
| 5773234 | Pronovost et al. | Jun 1998 | A |
| 5882903 | Andrevski et al. | Mar 1999 | A |
| 5922591 | Anderson et al. | Jul 1999 | A |
| 5952664 | Wake et al. | Sep 1999 | A |
| 5976470 | Maiefski et al. | Nov 1999 | A |
| 6039924 | Horn et al. | Mar 2000 | A |
| 6126804 | Andresen et al. | Oct 2000 | A |
| 6146591 | Miller et al. | Nov 2000 | A |
| 6153425 | Kozwich et al. | Nov 2000 | A |
| 6168760 | Horn et al. | Jan 2001 | B1 |
| 6235479 | Rogers | May 2001 | B1 |
| 6261431 | Mathies et al. | Jul 2001 | B1 |
| 6303081 | Mink et al. | Oct 2001 | B1 |
| 6313471 | Giebeler et al. | Nov 2001 | B1 |
| 6365378 | Hirota et al. | Apr 2002 | B1 |
| 6369893 | Christel et al. | Apr 2002 | B1 |
| 6374684 | Dority et al. | Apr 2002 | B1 |
| 6416718 | Maiefski et al. | Jul 2002 | B1 |
| 6426215 | Sandell et al. | Jul 2002 | B1 |
| 6514750 | Bordenkircher et al. | Feb 2003 | B2 |
| 6610499 | Fulwyler et al. | Aug 2003 | B1 |
| 6645758 | Schnipelsky et al. | Nov 2003 | B1 |
| 6649378 | Kozwich et al. | Nov 2003 | B1 |
| 6656744 | Pronovost et al. | Dec 2003 | B2 |
| 6677151 | Sandell et al. | Jan 2004 | B2 |
| 6680617 | Moreland et al. | Jan 2004 | B2 |
| 6767512 | Lurz et al. | Jul 2004 | B1 |
| 6780380 | Hunnell et al. | Aug 2004 | B2 |
| 6780617 | Chen et al. | Aug 2004 | B2 |
| 6781056 | O'Rourke et al. | Aug 2004 | B1 |
| 6813568 | Powell et al. | Nov 2004 | B2 |
| 6821771 | Festoc et al. | Nov 2004 | B2 |
| 6875403 | Liu et al. | Apr 2005 | B2 |
| 6893879 | Petersen et al. | May 2005 | B2 |
| 6901217 | Gamboa et al. | May 2005 | B2 |
| 6911181 | McNeil et al. | Jun 2005 | B1 |
| 6964862 | Chen et al. | Nov 2005 | B2 |
| 6990290 | Kylberg et al. | Jan 2006 | B2 |
| 7041481 | Anderson et al. | May 2006 | B2 |
| 7144742 | Boehringer et al. | Dec 2006 | B2 |
| 7179639 | Pottathil et al. | Feb 2007 | B2 |
| 7189522 | Esfandiari et al. | Mar 2007 | B2 |
| 7192721 | Esfandiari et al. | Mar 2007 | B1 |
| 7235216 | Kiselev et al. | Jun 2007 | B2 |
| 7297313 | Northrup et al. | Nov 2007 | B1 |
| 7341697 | Takeuchi et al. | Mar 2008 | B2 |
| 7377291 | Moon et al. | May 2008 | B2 |
| 7378285 | Lambotte et al. | May 2008 | B2 |
| 7384782 | Nakatani et al. | Jun 2008 | B2 |
| 7416892 | Battrell et al. | Aug 2008 | B2 |
| 7438852 | Tung et al. | Oct 2008 | B2 |
| 7459302 | Reid et al. | Dec 2008 | B2 |
| 7491551 | Boehringer et al. | Feb 2009 | B2 |
| 7517495 | Wu et al. | Apr 2009 | B2 |
| 7544324 | Tung et al. | Jun 2009 | B2 |
| 7550112 | Gou et al. | Jun 2009 | B2 |
| 7553675 | Jerome et al. | Jun 2009 | B2 |
| 7569382 | Li et al. | Aug 2009 | B2 |
| 7579172 | Cho et al. | Aug 2009 | B2 |
| 7592139 | West et al. | Sep 2009 | B2 |
| 7632687 | Gokhan et al. | Dec 2009 | B2 |
| 7648835 | Breidford et al. | Jan 2010 | B2 |
| 7682801 | Esfandiari et al. | Mar 2010 | B2 |
| 7691644 | Lambotte et al. | Apr 2010 | B2 |
| 7705339 | Smith et al. | Apr 2010 | B2 |
| 7709250 | Corbett et al. | May 2010 | B2 |
| 7754452 | Kim et al. | Jul 2010 | B2 |
| 7767439 | Oh et al. | Aug 2010 | B2 |
| 7794656 | Liang et al. | Sep 2010 | B2 |
| 7799521 | Chen | Sep 2010 | B2 |
| 7837939 | Tung et al. | Nov 2010 | B2 |
| 7858396 | Corstjens et al. | Dec 2010 | B2 |
| 7871568 | Liang et al. | Jan 2011 | B2 |
| 7879293 | Niedbala et al. | Feb 2011 | B2 |
| 7914986 | Nunn et al. | Mar 2011 | B2 |
| 7915013 | Cho et al. | Mar 2011 | B2 |
| 7935504 | Chen et al. | May 2011 | B2 |
| 7943348 | Cho et al. | May 2011 | B2 |
| 7959877 | Esfandiari et al. | Jun 2011 | B2 |
| 7985716 | Yershov et al. | Jul 2011 | B2 |
| 7988915 | Lee et al. | Aug 2011 | B2 |
| 7998757 | Darrigrand et al. | Aug 2011 | B2 |
| 8008046 | Maltezos et al. | Aug 2011 | B2 |
| 8008080 | Tokhtuev et al. | Aug 2011 | B2 |
| 8012427 | Bommarito et al. | Sep 2011 | B2 |
| 8018593 | Tan et al. | Sep 2011 | B2 |
| 8048386 | Dority et al. | Nov 2011 | B2 |
| 8062883 | Woudenberg et al. | Nov 2011 | B2 |
| 8075854 | Yang et al. | Dec 2011 | B2 |
| 8076129 | Hanafusa et al. | Dec 2011 | B2 |
| 8088616 | Handique et al. | Jan 2012 | B2 |
| 8110148 | Ball et al. | Feb 2012 | B2 |
| 8110392 | Battrell et al. | Feb 2012 | B2 |
| 8133671 | Williams et al. | Mar 2012 | B2 |
| 8133703 | Ching et al. | Mar 2012 | B2 |
| 8148116 | Chen et al. | Apr 2012 | B2 |
| 8163489 | Murray et al. | Apr 2012 | B2 |
| 8163535 | Reed et al. | Apr 2012 | B2 |
| 8169610 | Oldham et al. | May 2012 | B2 |
| 8173077 | Korampally et al. | May 2012 | B2 |
| 8187557 | Van Atta et al. | May 2012 | B2 |
| 8198074 | Moriwaki et al. | Jun 2012 | B2 |
| 8216832 | Battrell et al. | Jul 2012 | B2 |
| 8222023 | Battrell et al. | Jul 2012 | B2 |
| 8231844 | Gorfinkel et al. | Jul 2012 | B2 |
| 8232091 | Maltezos et al. | Jul 2012 | B2 |
| 8232094 | Hasson et al. | Jul 2012 | B2 |
| 8247221 | Fawcett et al. | Aug 2012 | B2 |
| 8263392 | Gale et al. | Sep 2012 | B2 |
| 8277763 | Steinmann et al. | Oct 2012 | B2 |
| 8278091 | Rutter et al. | Oct 2012 | B2 |
| 8298763 | Regan et al. | Oct 2012 | B2 |
| 8323583 | Gou et al. | Dec 2012 | B2 |
| 8329453 | Battrell et al. | Dec 2012 | B2 |
| 8343442 | McBride et al. | Jan 2013 | B2 |
| 8343754 | Wittwer et al. | Jan 2013 | B2 |
| 8357490 | Froehlich et al. | Jan 2013 | B2 |
| 8372340 | Bird et al. | Feb 2013 | B2 |
| 8389960 | Pieprzyk et al. | Mar 2013 | B2 |
| 8394322 | Windeyer et al. | Mar 2013 | B2 |
| 8394608 | Ririe et al. | Mar 2013 | B2 |
| 8394626 | Ramsey et al. | Mar 2013 | B2 |
| 8426134 | Piepenburg et al. | Apr 2013 | B2 |
| 8431413 | Dority et al. | Apr 2013 | B2 |
| 8435461 | Kirby et al. | May 2013 | B2 |
| 8448824 | Diperna et al. | May 2013 | B2 |
| 8492136 | Carlisle et al. | Jul 2013 | B2 |
| 8507259 | Esfandiari et al. | Aug 2013 | B2 |
| 8557518 | Jovanovich | Oct 2013 | B2 |
| 8580575 | Hanafusa et al. | Nov 2013 | B2 |
| 8597937 | Ward et al. | Dec 2013 | B2 |
| 8603835 | Esfandiari et al. | Dec 2013 | B2 |
| 8617486 | Kirby et al. | Dec 2013 | B2 |
| 8629264 | Reed et al. | Jan 2014 | B2 |
| 8637250 | Jenison et al. | Jan 2014 | B2 |
| 8663976 | Chung et al. | Mar 2014 | B2 |
| 8673238 | Dority et al. | Mar 2014 | B2 |
| 8673239 | Niedbala et al. | Mar 2014 | B2 |
| 8691561 | Igata et al. | Apr 2014 | B2 |
| 8722426 | Lambotte et al. | May 2014 | B2 |
| 8728765 | Ching et al. | May 2014 | B2 |
| 8735103 | Chung et al. | May 2014 | B2 |
| 8758701 | Van Atta et al. | Jun 2014 | B2 |
| 8765367 | Breidenthal | Jul 2014 | B2 |
| 8765454 | Zhou et al. | Jul 2014 | B2 |
| 8772017 | Battrell et al. | Jul 2014 | B2 |
| 8795592 | Eiriksson et al. | Aug 2014 | B2 |
| 8859199 | Hellyer et al. | Oct 2014 | B2 |
| 8865458 | Ramsey et al. | Oct 2014 | B2 |
| 8871155 | Wu et al. | Oct 2014 | B2 |
| 8877450 | Esfandiari et al. | Nov 2014 | B2 |
| 8894946 | Nielsen et al. | Nov 2014 | B2 |
| 8895255 | Goldberg et al. | Nov 2014 | B1 |
| 8900828 | Smith et al. | Dec 2014 | B2 |
| 8900853 | Verhaar et al. | Dec 2014 | B2 |
| 8911941 | Michlitsch et al. | Dec 2014 | B2 |
| 8911949 | Bertrand et al. | Dec 2014 | B2 |
| 8916375 | Landers et al. | Dec 2014 | B2 |
| 8945843 | Alvino et al. | Feb 2015 | B2 |
| 8975027 | Gale et al. | Mar 2015 | B2 |
| 8980177 | Carlisle et al. | Mar 2015 | B2 |
| 8980561 | Cai et al. | Mar 2015 | B1 |
| 8986927 | Lee et al. | Mar 2015 | B2 |
| 8992854 | Brewster et al. | Mar 2015 | B2 |
| 9011770 | Wu et al. | Apr 2015 | B2 |
| 9012236 | Jovanovich et al. | Apr 2015 | B2 |
| 9023639 | Kim et al. | May 2015 | B2 |
| 9044729 | Rengifo et al. | Jun 2015 | B2 |
| 9150907 | Shaikh | Oct 2015 | B2 |
| 9207236 | Cary | Dec 2015 | B2 |
| 9207241 | Lambotte et al. | Dec 2015 | B2 |
| 9238833 | Chen | Jan 2016 | B2 |
| 9243288 | Ness et al. | Jan 2016 | B2 |
| 9260750 | Hillebrand et al. | Feb 2016 | B2 |
| 9268911 | Sia et al. | Feb 2016 | B2 |
| 9387478 | Bergstedt et al. | Jul 2016 | B2 |
| 9428781 | Cai et al. | Aug 2016 | B2 |
| 9453255 | Ozawa | Sep 2016 | B2 |
| 9469871 | Bearinger et al. | Oct 2016 | B2 |
| 9475049 | Siciliano et al. | Oct 2016 | B2 |
| D776290 | Wan et al. | Jan 2017 | S |
| 9623415 | Andreyev et al. | Apr 2017 | B2 |
| 9752182 | Collier et al. | Sep 2017 | B2 |
| 10040069 | Moore et al. | Aug 2018 | B2 |
| 10173182 | Tachibana et al. | Jan 2019 | B2 |
| 10195610 | Tang et al. | Feb 2019 | B2 |
| 10603664 | Khattak et al. | Mar 2020 | B2 |
| 20010055799 | Baunoch et al. | Dec 2001 | A1 |
| 20020086417 | Chen et al. | Jul 2002 | A1 |
| 20030027244 | Colston et al. | Feb 2003 | A1 |
| 20040018502 | Makino et al. | Jan 2004 | A1 |
| 20040110141 | Pusey et al. | Jun 2004 | A1 |
| 20040209331 | Ririe | Oct 2004 | A1 |
| 20040224317 | Kordunsky et al. | Nov 2004 | A1 |
| 20040251426 | Birk et al. | Dec 2004 | A1 |
| 20050019875 | Chen et al. | Jan 2005 | A1 |
| 20050064598 | Yuan et al. | Mar 2005 | A1 |
| 20050100946 | Lipshutz et al. | May 2005 | A1 |
| 20050142036 | Kim et al. | Jun 2005 | A1 |
| 20050194316 | Pourahmadi et al. | Sep 2005 | A1 |
| 20050227275 | Jung et al. | Oct 2005 | A1 |
| 20060001689 | Ahne et al. | Jan 2006 | A1 |
| 20060088931 | Ririe et al. | Apr 2006 | A1 |
| 20060127924 | Hellyer et al. | Jun 2006 | A1 |
| 20060154341 | Chen et al. | Jul 2006 | A1 |
| 20060160205 | Blackburn et al. | Jul 2006 | A1 |
| 20060177841 | Wangh et al. | Aug 2006 | A1 |
| 20060246493 | Jensen et al. | Nov 2006 | A1 |
| 20060258012 | Yang et al. | Nov 2006 | A1 |
| 20070026391 | Stoughton et al. | Feb 2007 | A1 |
| 20070042427 | Gerdes et al. | Feb 2007 | A1 |
| 20070154922 | Collier et al. | Jul 2007 | A1 |
| 20070277251 | Wartiovaara et al. | Nov 2007 | A1 |
| 20070284360 | Santoruvo et al. | Dec 2007 | A1 |
| 20070292941 | Handique et al. | Dec 2007 | A1 |
| 20080026451 | Braman et al. | Jan 2008 | A1 |
| 20080038737 | Smith et al. | Feb 2008 | A1 |
| 20080043235 | Oldham et al. | Feb 2008 | A1 |
| 20080050735 | Pushnova et al. | Feb 2008 | A1 |
| 20080057572 | Petersen et al. | Mar 2008 | A1 |
| 20080113391 | Gibbons et al. | May 2008 | A1 |
| 20080145852 | Shuber et al. | Jun 2008 | A1 |
| 20080153078 | Braman et al. | Jun 2008 | A1 |
| 20080220468 | Windeyer et al. | Sep 2008 | A1 |
| 20080274513 | Shenderov | Nov 2008 | A1 |
| 20080280285 | Chen et al. | Nov 2008 | A1 |
| 20090029422 | Hanafusa et al. | Jan 2009 | A1 |
| 20090042256 | Hanafusa et al. | Feb 2009 | A1 |
| 20090130745 | Williams et al. | May 2009 | A1 |
| 20090186344 | Farinas | Jul 2009 | A1 |
| 20090215072 | McDevitt et al. | Aug 2009 | A1 |
| 20090325276 | Battrell et al. | Dec 2009 | A1 |
| 20100003683 | Sarofim et al. | Jan 2010 | A1 |
| 20100113762 | Ball et al. | May 2010 | A1 |
| 20100173393 | Handique et al. | Jul 2010 | A1 |
| 20100210038 | Blatt et al. | Aug 2010 | A1 |
| 20100291588 | McDevitt et al. | Nov 2010 | A1 |
| 20100297640 | Kumar et al. | Nov 2010 | A1 |
| 20110020876 | Wilding et al. | Jan 2011 | A1 |
| 20110039303 | Jovanovich et al. | Feb 2011 | A1 |
| 20110160090 | Cary | Jun 2011 | A1 |
| 20110203688 | Reed et al. | Aug 2011 | A1 |
| 20110207121 | Chen et al. | Aug 2011 | A1 |
| 20110211331 | Alkjaer et al. | Sep 2011 | A1 |
| 20110227551 | Black et al. | Sep 2011 | A1 |
| 20110269191 | Belgrader et al. | Nov 2011 | A1 |
| 20110275055 | Conner | Nov 2011 | A1 |
| 20110300545 | Cano et al. | Dec 2011 | A1 |
| 20110312666 | Azimi et al. | Dec 2011 | A1 |
| 20110312793 | Azimi et al. | Dec 2011 | A1 |
| 20110312841 | Silverbrook et al. | Dec 2011 | A1 |
| 20110313148 | Christ et al. | Dec 2011 | A1 |
| 20120021454 | Bikker et al. | Jan 2012 | A1 |
| 20120064534 | Pipper et al. | Mar 2012 | A1 |
| 20120070878 | Fink et al. | Mar 2012 | A1 |
| 20120088294 | Sun et al. | Apr 2012 | A1 |
| 20120115738 | Zhou et al. | May 2012 | A1 |
| 20120130061 | Himmelreich et al. | May 2012 | A1 |
| 20120135511 | Battrell et al. | May 2012 | A1 |
| 20120141337 | Maltezos et al. | Jun 2012 | A1 |
| 20120237939 | Reed et al. | Sep 2012 | A1 |
| 20120264202 | Walker et al. | Oct 2012 | A1 |
| 20120276532 | Chen et al. | Nov 2012 | A1 |
| 20120282684 | Fritchie et al. | Nov 2012 | A1 |
| 20120288897 | Ching et al. | Nov 2012 | A1 |
| 20130040296 | Tulp et al. | Feb 2013 | A1 |
| 20130053255 | Vangbo et al. | Feb 2013 | A1 |
| 20130059290 | Armes | Mar 2013 | A1 |
| 20130078736 | Grover et al. | Mar 2013 | A1 |
| 20130115712 | Yu et al. | May 2013 | A1 |
| 20130118900 | Reimitz et al. | May 2013 | A1 |
| 20130149710 | Yoon et al. | Jun 2013 | A1 |
| 20130171640 | Kwon et al. | Jul 2013 | A1 |
| 20130210080 | Rajagopal et al. | Aug 2013 | A1 |
| 20130217026 | Egan et al. | Aug 2013 | A1 |
| 20130220781 | Czarnecki et al. | Aug 2013 | A1 |
| 20130225801 | Christoffel | Aug 2013 | A1 |
| 20140045191 | Dejohn et al. | Feb 2014 | A1 |
| 20140051159 | Bergstedt et al. | Feb 2014 | A1 |
| 20140073013 | Gorman et al. | Mar 2014 | A1 |
| 20140087359 | Njoroge et al. | Mar 2014 | A1 |
| 20140098252 | Chang et al. | Apr 2014 | A1 |
| 20140120539 | Tanner et al. | May 2014 | A1 |
| 20140199685 | Lambotte et al. | Jul 2014 | A1 |
| 20140274770 | Pack | Sep 2014 | A1 |
| 20150031087 | Nagai et al. | Jan 2015 | A1 |
| 20150176057 | Smith et al. | Jun 2015 | A1 |
| 20150182966 | Coursey et al. | Jul 2015 | A1 |
| 20150240298 | Piepenburg et al. | Aug 2015 | A1 |
| 20150258273 | Payne et al. | Sep 2015 | A1 |
| 20150322483 | Nakamura et al. | Nov 2015 | A1 |
| 20150346097 | Battrell et al. | Dec 2015 | A1 |
| 20150361419 | Kim et al. | Dec 2015 | A1 |
| 20160054316 | Egan et al. | Feb 2016 | A1 |
| 20160186240 | Andreyev et al. | Jun 2016 | A1 |
| 20160222442 | Cary | Aug 2016 | A1 |
| 20160256870 | Ismagilov | Sep 2016 | A1 |
| 20160289669 | Fan | Oct 2016 | A1 |
| 20160310948 | Nowakowski et al. | Oct 2016 | A1 |
| 20170021356 | Dority et al. | Jan 2017 | A1 |
| 20170058324 | Balog et al. | Mar 2017 | A1 |
| 20170173585 | Mahony et al. | Jun 2017 | A1 |
| 20170173588 | Tang et al. | Jun 2017 | A1 |
| 20170203297 | Andreyev et al. | Jul 2017 | A1 |
| 20170247745 | Shultz et al. | Aug 2017 | A1 |
| 20170259263 | Andreyev et al. | Sep 2017 | A1 |
| 20170304829 | Andreyev et al. | Oct 2017 | A1 |
| 20180071734 | Andreyev et al. | Mar 2018 | A1 |
| 20180117590 | Andreyev et al. | May 2018 | A1 |
| 20190022643 | Andreyev et al. | Jan 2019 | A1 |
| 20190030532 | Andreyev et al. | Jan 2019 | A1 |
| 20190136226 | Swenson et al. | May 2019 | A1 |
| 20190151844 | Andreyev et al. | May 2019 | A1 |
| 20190169677 | Andreyev et al. | Jun 2019 | A1 |
| 20190193077 | Andreyev et al. | Jun 2019 | A1 |
| 20190232283 | Andreyev et al. | Aug 2019 | A1 |
| 20200086324 | Swenson et al. | Mar 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 101538567 | Sep 2009 | CN |
| 105239164 | Jan 2016 | CN |
| 1347833 | Oct 2011 | EP |
| 2614147 | Jul 2013 | EP |
| 2682480 | Jan 2014 | EP |
| 2682480 | Jan 2014 | EP |
| 20100079360 | Jul 2010 | KR |
| WO-0149416 | Jul 2001 | WO |
| WO-2008149111 | Dec 2008 | WO |
| WO-2009047804 | Apr 2009 | WO |
| WO-2014035986 | Mar 2014 | WO |
| WO-2014144548 | Sep 2014 | WO |
| WO-2015138343 | Sep 2015 | WO |
| WO-2015138648 | Sep 2015 | WO |
| WO-2015164770 | Oct 2015 | WO |
| WO-2016040523 | Mar 2016 | WO |
| WO-2016109691 | Jul 2016 | WO |
| WO-2016203019 | Dec 2016 | WO |
| WO-2017197040 | Nov 2017 | WO |
| WO-2018005870 | Jan 2018 | WO |
| Entry |
|---|
| Advisory Action for U.S. Appl. No. 15/474,083, dated Mar. 26, 2018. |
| BioiFire Online Demo FilmArray. http://filmarray.com/the-evidence/online-demo. 2014, 6 pages. |
| Co-pending U.S. Appl. No. 16/186,240, filed Nov. 9, 2018. |
| Co-pending U.S. Appl. No. 16/234,453, filed Dec. 27, 2018. |
| Final Office Action for U.S. Appl. No. 15/474,083, dated Jan. 25, 2018. |
| Gehring, et al., A High-Throughput, Precipitating Colorimetric Sandwich ELISA Microarray for Shiga Toxins, J. Toxins, vol. 6, p. 1855-72, Jun. 11, 2014. |
| Hwang et al., “Black Printed Circuit Board-based Micro-Polymerase Chain Reaction Chip Structure for Fluorescence Detection Test”, International Journal of Control and Automation, 8(10):15-24, 2015. |
| Interbiotech, “Enzymatic substrates for ImmunoAssays,” [retreived from the Internet Nov. 18, 2017:< http://www.interchim.fr/ft/B/BA357a.pdf], 10 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2017/029004, dated Aug. 23, 2017. |
| International Search Report and Written Opinion for International Application No. PCT/US2017/039844, dated Dec. 7, 2017. |
| Kim, et al., Automated microfluidic DNA/RNA extraction with both disposable and reusable components. Journal of Micromechanics and Microengineering, Dec. 2011; 22(1):pp. 6,8,11. |
| Kopp et al., Chemical amplification: Continuous-flow PCR on a chip. Science, 280(5366):1046-1048, 1998. |
| Lee, et al., A polymer lab-on-a-chip for reverse transcription (RT)-PCR based point-of-care clinical diagnostics. The Royal Society of Chemistry, Oct. 2008; 8:2121-27. |
| Mohammed, et al., Modelling of Serpentine Continuous Flow Polymerase Chain Reaction Microfluidics. IJEST, Mar. 2012; 4(3), pp. 1183-1189. |
| Non-final Office Action for U.S. Appl. No. 15/474,083, dated Aug. 24, 2017. |
| Office Action for U.S. Appl. No. 15/586,780, dated Feb. 6, 2018. |
| PCT Patent Application No. PCT/US2015/019497 International Search Report and Written Opinion dated Jun. 8, 2015. |
| PCT Patent Application No. PCT/US2015/049247 International Search Report and Written Opinion dated Jan. 12, 2016. |
| PCT/US2015/019497 International Preliminary Report on Patentability dated Sep. 13, 2016. |
| PCT/US2015/049247 International Preliminary Report on Patentability dated Mar. 14, 2017. |
| PCT/US2015/068101 International Preliminary Report on Patentability dated Jul. 13, 2017. |
| PCT/US2015/068101 International Search Report and Written Opinion dated May 5, 2016. |
| PCT/US2017/032035 International Search Report and Written Opinion dated Oct. 4, 2017. |
| PCT/US2017/040112 International Search Report and Written Opinion dated Nov. 9, 2017. |
| Schwerdt. Application of ferrofluid as a valve/pump for polycarbonate microfluidic devices. Johns Hopkins University. NSF Summer Undergraduate Fellowship in Sensor Technologies 2006, 17 pages. |
| Shafagati, et al., The Use of NanoTrap Particles as a Sample Enrichment Method to Enhance the Detection of Rift Valley Fever Virus. PLOS Negrlected Tropical Diseases, Jul. 4, 2013;7(7): e2296. |
| Tanriverdi, et al. A rapid and automated sample-to-result HIV load test for near-patient application. J Infect Dis., 201 Suppl 1:S52-S58, 2010. doi: 10.1086/650387. |
| Thiha, et al., A Colorimetric Enzyme-Linked Immunosorbent Assay (ELISA) Detection Platform for a Point-of-Care Dengue Detection System on a Lab-on-Compact-Disc. Sensors (Basel). May 18, 2015;15(5):11431-41. doi: 10.3390/s150511431. |
| U.S. Appl. No. 15/124,334 Notice of Allowance dated Sep. 26, 2018. |
| U.S. Appl. No. 14/984,573 First Action Interview Pilot Program Pre-Interview Communication dated Aug. 16, 2016. |
| U.S. Appl. No. 14/984,573 Notice of Allowance dated Feb. 10, 2017. |
| U.S. Appl. No. 14/984,573 Office Action dated Aug. 16, 2016. |
| EP15876276.5 Extended European Search Report dated Aug. 7, 2018. |
| Invitation to Pay Additional Fees for International Application No. PCT/US18/60117, dated Feb. 8, 2019. |
| Kim, Yong Tae et al. “Integrated Microevidence of reverse transcription-polymerase chain reaction with colorimetric immunochromatographic detection for rapid gene expression analysis of influenza A H1N1 virus,” Biosensors and Bioelectronics, Elsevier Science Ltd UK, Amsterdam, NL V. 33 No. 1, pp. 88-94, Dec. 14, 2011. |
| Petralia, Salvatore et al. “PCR Technologies for Point of Care Testing: Progress and Perspectives,” ACS Sensors, 2017, 2 (7), pp. 876-891, Jul. 6, 2017. |
| U.S. Appl. No. 15/510,479 Office Action dated Mar. 27, 2019. |
| Office Action for U.S. Appl. No. 15/510,479, dated Mar. 27, 2019. |
| Brunklaus, S. et al., Fast nucleic acid amplification for integration in point-of-care applications, Electrophoresis, 2012, vol. 33, pp. 3222-3228. |
| Lee et al. “Single-channel multiplexing without melting curve analysis in real-time PCR,” Scientific Reports, Dec. 11, 2014, vol. 4, Art. No. 7439, pp. 1-6, entire document. |
| Huang et al., “Efficient SNP Discovery by Combining Microarray and Lab-on-a-Chip Data for Animal Breeding and Selection,” Microarrays, Nov. 16, 2015, vol. 4, No. 4, pp. 570-595, entire document. |
| Kim, Yong Tae et al. “Integrated Microdevice of reverse transcription-polymerase chain reaction with colorimetric immunochromatographic detection for rapid gene expression analysis of influenza A H1N1 virus,” Biosensors and Bioelectronics, Elsevier Science Ltd UK, Amsterdam, NL V. 33 No. 1, pp. 88-94, Dec. 14, 2011. |
| Roskos, Kristina et al. “Simple System for Isothermal DNA Amplification Coupled to Lateral Flow Detection,” PLoS ONE 8(7): e69355. https://doi.org/10.1371/journal.pone.0069355; Jul. 26, 2013, 11 pages. |
| Wheeler, E.K., ‘Under-three minute PCR: Probing the limits of fast amplification’, published Jul. 27, 2011 by the Royal Society of Chemistry: Analyst 2011 vol. 136 pp. 3707-3712. |
| Moschou D., et al., ‘All-plastic, low-power, disposable, continuous-flow PCR chip with integrated microheaters for rapid DNA amplification’, Sensors and Actuators B: Chemical, vol. 199, 1 Aug. 2014, pp. 470-478. |
| Number | Date | Country | |
|---|---|---|---|
| 20190232293 A1 | Aug 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61950769 | Mar 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15124334 | US | |
| Child | 16228709 | US |
